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A B S T R A C T
Background
It is becoming increasingly common to publish information about the quality and performance of healthcare organisations and
individual professionals. However, we do not know how this information is used, or the extent to which such reporting leads to quality
improvement by changing the behaviour of healthcare consumers, providers, and purchasers.
Objectives
To estimate the effects of public release of performance data, from any source, on changing the healthcare utilisation behaviour of
healthcare consumers, providers (professionals and organisations), and purchasers of care. In addition, we sought to estimate the effects
on healthcare provider performance, patient outcomes, and staff morale.
Search methods
We searched CENTRAL, MEDLINE, Embase, and two trials registers on 26 June 2017. We checked reference lists of all included
studies to identify additional studies.
Selection criteria
We searched for randomised or non-randomised trials, interrupted time series, and controlled before-after studies of the effects of
publicly releasing data regarding any aspect of the performance of healthcare organisations or professionals. Each study had to report
at least one main outcome related to selecting or changing care.
Data collection and analysis
Two review authors independently screened studies for eligibility and extracted data. For each study, we extracted data about the target
groups (healthcare consumers, healthcare providers, and healthcare purchasers), performance data, main outcomes (choice of healthcare
provider, and improvement by means of changes in care), and other outcomes (awareness, attitude, knowledge of performance data,
and costs). Given the substantial degree of clinical and methodological heterogeneity between the studies, we presented the findings
for each policy in a structured format, but did not undertake a meta-analysis.
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Main results
We included 12 studies that analysed data frommore than 7570 providers (e.g. professionals and organisations), and a further 3,333,386
clinical encounters (e.g. patient referrals, prescriptions). We included four cluster-randomised trials, one cluster-non-randomised trial,
six interrupted time series studies, and one controlled before-after study. Eight studies were undertaken in the USA, and one each in
Canada, Korea, China, and The Netherlands. Four studies examined the effect of public release of performance data on consumer
healthcare choices, and four on improving quality.
There was low-certainty evidence that public release of performance data may make little or no difference to long-term healthcare
utilisation by healthcare consumers (3 studies; 18,294 insurance plan beneficiaries), or providers (4 studies; 3,000,000 births, and 67
healthcare providers), or to provider performance (1 study; 82 providers). However, there was also low-certainty evidence to suggest
that public release of performance data may slightly improve some patient outcomes (5 studies, 315,092 hospitalisations, and 7502
providers). There was low-certainty evidence from a single study to suggest that public release of performance data may have differential
effects on disadvantaged populations. There was no evidence about effects on healthcare utilisation decisions by purchasers, or adverse
effects.
Authors’ conclusions
The existing evidence base is inadequate to directly inform policy and practice. Further studies should consider whether public release
of performance data can improve patient outcomes, as well as healthcare processes.
P L A I N L A N G U A G E S U M M A R Y
Can the public release of performance data in health care influence the behaviour of consumers, healthcare providers, and
organisations?
What is the aim of this review?
The aim was to find out if publicly releasing information about the performance of healthcare providers (e.g. hospitals and individual
professionals) has a measurable influence on changing the behaviour of consumers, providers, and purchasers of care. We also sought
to determine whether this affected the performance of healthcare providers, patient outcomes, and staff morale.
Key messages
Public release of performance data may lead to little or no difference in healthcare choices (made by either consumers or providers), or
provider performance. However, it may slightly improve outcomes for patients.
What was studied in the review?
Healthcare providers are increasingly expected to inform the public on how well they are performing. However, it is not yet known
whether public release of performance data has a measurable influence on patients’ choice of healthcare services, or whether it can truly
drive improvements in the quality of health care.
What are the main results of the review?
The authors searched the literature for studies evaluating the effects of publicly releasing healthcare performance information, and
found 12 relevant studies that analysed data frommore than 7570 providers, and a further 3,333,386 clinical encounters, e.g. individual
patients.
There was low-certainty evidence that public release of performance data may lead to little or no difference in the services that patients
choose to access, the decisions taken by healthcare providers, or overall provider performance. There was low-certainty evidence
suggesting that some patient outcomes may slightly improve following public release of performance data, but that this might have
less of an effect on the behaviour of disadvantaged populations. There was no evidence relating to healthcare utilisation decisions by
purchasers, or adverse effects.
Although a number of the studies were individually well conducted, there were limitations: in particular, the evidence base varied
substantially in terms of setting (e.g. United States or Korea), health condition (e.g. heart attack or hip replacement), type of performance
data (e.g. process or patient outcome), and the mode of data publication (e.g. mail shot or poster). Their findings were also inconsistent,
with some reporting changes attributed to public release of information, and others reporting no such changes.
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How up-to-date is this review?
The review authors searched for studies that had been published up to June 2017.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
People: Insurance plan benef iciaries, birthing mothers, GPs
Settings (countries and clinical settings): United States, Canada, South Korea, Netherlands, China / Community, primary care and hospitals
Intervention: Public release of performance data
Comparison: No public report ing
Outcomes Impact No of clinical encounters
(studies)
Certainty of the evidence
(GRADE)*
Changes in healthcare ut ilisat ion by con-
sumers
Public release of performance data may
make lit t le or no dif ference to long-term
healthcare ut ilisat ion by consumers. How-
ever, two studies (one cNRT and one ITS)
found that some populat ion subgroups
might be inf luenced by public release of
performance data
18,294 insurance plan benef iciariesa
(3: 1 cRT, 1 cNRT, 1 ITS)
⊕⊕©©
low
Changes in healthcare decisions taken by
healthcare providers (professionals and
organisat ions)
Public release of performance data may
make lit t le or no dif ference to decisions
taken by healthcare professionals. Two
studies (2 cRTs) found that some de-
cisions might be af fected by public re-
lease of performance data. One study (ITS)
found that decisions might be inf luenced
by the init ial release of data, but that sub-
sequent releases might have less impact
3,000,000 birthsb and 67 healthcare
providers (4: 2 RTs, 2 ITS)
⊕⊕©©
lowc
Changes in the healthcare ut ilisat ion deci-
sions of purchasers
No studies reported this outcome. - -
Changes in provider performance Public release of performance data may
make lit t le or no dif ference to object ive
measures of provider performance
82 healthcare providers
(1 cRT)
⊕⊕©©
lowd
Changes in pat ient outcome Public release of performance data may
slight ly improve pat ient outcomes
315,092 hospitalisat ions and 7503 health-
care providers (5: 1 RT, 3 ITS, 1 CBA)
⊕⊕©©
lowe
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Adverse ef fects No studies reported this outcome. - -
Impact on equity Public release of performance data may
have a greater ef fect on provider choice
among advantaged populat ions
Unknown (1 ITS) ⊕⊕©©
low
EPOC adapted statements for GRADE Working Group grades of evidence
High-certainty. This research provides a very good indicat ion of the likely ef fect. The likelihood that the ef fect will be substant ially dif f erent† is low.
Moderate-certainty. This research provides a good indicat ion of the likely ef fect. The likelihood that the ef fect will be substant ially dif f erent† is moderate.
Low-certainty. This research provides some indicat ion of the likely ef fect. However, the likelihood that it will be substant ially dif f erent† is high.
Very low-certainty. This research does not provide a reliable indicat ion of the likely ef fect. The likelihood that the ef fect will be substant ially dif f erent† is very high.
† Substant ially dif f erent = a large enough dif ference that it m ight af fect a decision
a Number was based only on Farley 2002a and Farley 2002b studies, as the total number of cases analysed in Romano 2004 was unclear
b Number of part icipants in Jang 2011 (3,000,000) est imated f rom data presented in Chung 2014
c Downgraded one level for inconsistency as ef fect shown by Zhang 2016, but not IkkersheJang 2011, Ikkersheim 2013, or Flett 201511
d Downgraded two levels for risk of bias, as there was attrit ion of part icipat ing hospitals, evidence of contaminat ion of the intervent ion across intervent ion and control
hospitals, and blinding was not possible given the nature of the intervent ion
e Downgraded two levels for inconsistency, as there was marked disagreement between studies, with two showing improvements in pat ient outcome (Liu Tu 2009; Liu 20179),
and three showing no such improvements (DeVoRinke 2015; DeVore 2016; Joynt 201615)
cluster-randomised trial (cRT); cluster-non-randomised trial (cNRT); controlled before-af ter (CBA) study; interrupted t ime
series (ITS) study; randomised trial (RT)
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B A C K G R O U N D
It is becoming increasingly common to release information about
the performance of healthcare systems into the public domain.
In the present era of accountability, cost-effectiveness, quality im-
provement, and demand-driven healthcare systems, decision mak-
ers such as governments, regulators, purchaser and provider or-
ganisations, health professionals, and consumers of health care
are becoming more interested in measuring performance (Smith
2009). Suchmeasurementsmay be presented in consumer reports,
provider profiles, or report cards. It is not always clear who the
information users are or what the release of data is expected to
achieve. However, it is often assumed that the information will
influence the behaviours of various stakeholders, and so ultimately
lead to health system improvements (Berwick 2003; Smith 2009;
Campanella 2016).
One study has conceptualised public reporting of performance
data as (1) supportingpatient choice, (2) improving accountability,
and (3) allowingproviders to benchmark their performance against
others (Greenhalgh 2018).
Publication of performance data can support patient choice by
helping them to identify the highest performing providers. How-
ever, there are many barriers to patient use of performance data
(Canaway 2017). These include the complexity of the perfor-
mance data (Hibbard 2010), lack of skills to comprehend and
use performance data (Hibbard 2007; Canaway 2017; Canaway
2018), and the way data are presented (Damman 2010; Canaway
2017; Canaway 2018). Such barriers might negate the impact of
choice, and even reduce equity in health care. Consumers from
poorer backgrounds and with lower educational levels may be less
able to choose, and less able to afford travel to better perform-
ing, but more distant, providers (Aggarwal 2017; Moscelli 2017).
There is also evidence that patients often do not use published
performance data when making healthcare choices (Greenhalgh
2018).
Improved accountability may be achieved by encouraging
providers to focus on quality issues, as they know that perfor-
mance measures will be published (Fung 2008; Hendriks 2009).
This in turn, may stimulate quality improvements, particularly as
providers can see their own performance against that of other clin-
icians and hospitals. Similarly, patients who preferentially choose
high-quality health care might help drive improvements, by con-
centrating resources with the best performing providers (Hibbard
2009; Kolstad 2009; Werner 2009).
Other proposed goals for performance measurements have been
linked to controlling costs (Berwick 1990; Sirio 1996), regulating
the overall healthcare system (Rosenthal 1998; Schut 2005), and
influencing the decisions of healthcare purchasers (Brook 1994;
Hibbard 1997; Mukamel 1998).
Professional concerns to public release of performance data of-
ten relate to the validity of both the performance measures them-
selves, and comparisons between health providers (Sherman 2013;
Kiernan 2015; Burns 2016;). There are concerns that failure to ad-
equately adjust for casemix differencesmight lead to providers that
treat higher-risk patients being labelled as poor performers, or to
providers preferentially selecting lower-risk patients (Wasfy 2015;
Burns 2016; Shahian 2017;Wadhera 2017). In healthcare systems
where providers charge for their services, the ’better’ performing
providers might feel empowered to increase charges, thereby re-
stricting access to better care (Mukamel 1998). An additional risk
is that publication of performance data may lead to improved re-
porting, without necessarily improving performance. It has been
argued that the care processes that are easiest to measure are often
those that are least important in a quality improvement context,
and can result in the de-prioritisation of other tasks (Loeb 2004).
Description of the intervention
Public release of performance data is the release of information
about the quality of care, so that patients and consumers can bet-
ter decide what health care they wish to select, and healthcare
professionals and organisations can better decide what to provide,
improve, or purchase. This mechanism excludes the use of audit-
ing and feedback as a tool for improving professional practice and
healthcare outcomes, which has been reviewed elsewhere (Ivers
2012).
How the intervention might work
Public release of performance data may change individual or or-
ganisational behaviour through a number of mechanisms. The
goal of improving quality of health care can be achieved through
a selection pathway or a change pathway (Berwick 2003). Con-
sumers, patients, and purchaser organisations that are in a position
to do so, can select the best healthcare professionals and organi-
sations. This type of selection will not change the quality of the
delivered care by itself, but it can be a stimulus for quality im-
provement. Importantly, such changes might be attenuated by the
limited choice that patients have in many cases, e.g. in the case of
emergencies, the need to access specialised care that is only avail-
able in few centres, or because of resource limitations (Aggarwal
2017; Moscelli 2017). In a change pathway, healthcare profes-
sionals and organisations can improve performance by changing
their work procedures or professional culture, and organisations
can make structural changes.
Why it is important to do this review
Some systematic reviews have suggested positive effects of publicly
releasing performance data, but included a broad range of study
designs (Marshall 2000; Shekelle 2008; Fung 2008; Faber 2009).
This study (which is the first update of Ketelaar 2011) aimed to
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review the evidence for the impact of such interventions using
more stringent selection criteria.
O B J E C T I V E S
To estimate the effects of publicly releasing performance data
on changing the healthcare utilisation behaviour of healthcare
consumers, providers (professionals and organisations), and pur-
chasers of care. In addition, we sought to estimate the effects
on healthcare provider performance, patient outcomes, and staff
morale.
M E T H O D S
Criteria for considering studies for this review
Types of studies
• Randomised trials, including cluster-randomised trials
• Non-randomised trials, including cluster-non-randomised
trials, which use non-random methods of allocation, such as
alternation or allocation by case note number
• Controlled before-after studies, with at least two
intervention sites and two control sites that are chosen for
similarity of main outcome measures at baseline
• Interrupted time series studies, with at least three data
points before and three data points after the intervention
We included non-randomised studies in anticipation of a lack of
randomised trials, but also because some interventions might not
be appropriate for a trial (e.g. randomising participants to not
receive important information that might affect their healthcare
choices), and others might have a variable effect over time that is
best observed by an alternative study design, such as an interrupted
time series.
Types of participants
Patients or other healthcare consumers and healthcare providers,
including organisations (e.g. hospitals), without any restriction by
type of healthcare professional, provider, setting, or purchaser.
Types of interventions
We included interventions that contained the following elements:
• Performance data about any aspect of the healthcare
organisations or individuals, including process measures (e.g.
waiting times), healthcare outcomes (e.g. mortality), structure
measures (e.g. presence of waiting rooms), consumer or patient
experiences (e.g. Consumer Assessment of Healthcare Providers
and System (CAHPS) data), with or without expert or peer-
assessed measures, e.g. certification, accreditation, and quality
ratings given by colleagues. Performance data were included if
prepared and released by any organisation, such as the
government, insurers, consumer organisations, or providers. We
excluded studies that did not evaluate publication of
performance data concerning process measures, healthcare
outcomes, structure measure, consumer or patient experiences,
or expert or peer-assessed measures.
• The release of performance data into the public domain in
written or electronic form without regard to any minimum
degree of accessibility. For example, this could include a report
available in a publicly accessible library, as well as active
dissemination directly to consumers through personal mailings.
Comparators
The following comparisons were planned:
1. Public release of performance data compared to settings in
which data were not released to the public
2. Different modes of releasing performance data to the public
Types of outcome measures
Primary outcomes
We planned the primary outcome measures according to two key
aims of publicly releasing performance data.
1. Improvement by selection
• Changes in healthcare utilisation by consumers
◦ Objective measures of changing consumer behaviour,
such as increased use of a specific healthcare provider
• Changes in healthcare decisions taken by healthcare
providers (professionals and organisations)
◦ Objective measures of changing healthcare provider
behaviour, such as changes to drug prescribing
• Changes in the healthcare utilisation decisions of purchasers
◦ Objective measures of changing purchaser behaviour,
such as increased or decreased funding for services
2. Improvement by changes in care
• Changes in provider performance
◦ Objective changes, such as reaching the correct
diagnosis or time to treatment
◦ Including measures that were made both public and
others that were not
• Changes in patient outcome
◦ Objective changes, such as mortality or patient-
reported outcome measures
• Changes in staff morale
◦ Using a previously validated assessment tool
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Secondary outcomes
We considered unintended and adverse effects or harms, and any
potential impact on equity (e.g. differential effects between advan-
taged and disadvantaged populations), and awareness, knowledge,
attitude, or costs.
We excluded studies that reported awareness, attitude, perspec-
tives, and knowledge of performance data and cost data in the
absence of objective measures of decision behaviour, provider per-
formance or patient outcomes.
Search methods for identification of studies
Electronic searches
We searched the Database of Abstracts of Reviews of Effects
(DARE) for primary studies included in related systematic reviews.
We searched the following databases on 26 June 2017:
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2017, Issue 5) in the Cochrane Library;
• MEDLINE Ovid (including Epub Ahead of Print, In-
Process & Other Non-Indexed Citations and Versions);
• Embase Ovid.
The Cochrane Effective Practice and Organisation of Care
(EPOC) Information Specialist developed the search strategies in
consultation with the authors. Search strategies are comprised of
keywords and controlled vocabulary terms. We applied no lan-
guage or time limits. We searched all databases from database start
date to 26 June 2017.
Searching other resources
Trial Registries
• International Clinical Trials Registry Platform (ICTRP),
Word Health Organization (WHO) www.who.int/ictrp/en/
(searched 26 June 2017)
• ClinicalTrials.gov, US National Institutes of Health (NIH)
clinicaltrials.gov/ (searched 26 June 2017)
We manually searched the reference lists of all included studies.
We provided all search strategies used in Appendix 1.
Data collection and analysis
Selection of studies
We downloaded all titles and abstracts retrieved in the electronic
search to a reference management database. We removed the du-
plicates, and two review authors then independently examined
the remaining references. All review authors recorded their assess-
ments of abstracts with points: ‘0’ for exclusion, ‘1’ for doubtful
and ‘2’ for inclusion. Two review authors (DM, ARD) indepen-
dently rated each abstract; therefore, a minimum score of zero,
and a maximum score of four was possible. Abstracts with a com-
bined score of zero or one were excluded. Studies with a combined
score of three or four were included. Two review authors resolved
the fate of studies with a combined score of two by discussion. A
third review author (OO) adjudicated on any disagreements that
remained unresolved. Figure 1 shows the PRISMA flow diagram
that accounts for exclusion of all items received by the search strat-
egy.
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Figure 1. Flowchart for study selection
Data extraction and management
Two authors (DM, OO) independently extracted the data about
the study design, patient and provider characteristics, interven-
tions, outcome measures, and healthcare choices to a form spe-
cially designed for our review. Disagreements were resolved by dis-
cussion, and we accepted the judgement of a third author (ARD)
in the event of continued disagreement.
Assessment of risk of bias in included studies
Weassessed risk of bias by applying the guidance from theCochrane
Handbook for Systematic Reviews of Interventions, which recom-
mends using the following items: (i) adequate sequence genera-
tion, (ii) concealment of allocation, (iii) blinding, (iv) incomplete
outcome data, (v) selective reporting, and (vi) no risk of bias from
other sources (Higgins 2011). However, we deviated from this
guidance: we used three additional criteria that are specified by
the Cochrane Effective Practice and Organisation of Care Group:
(vii) baseline characteristic similarity, (viii) baseline outcome simi-
larity, and (ix) adequate protection against contamination (EPOC
2013). We used these nine standard criteria for randomised tri-
als, non-randomised trials, and controlled before-after studies. We
used seven criteria for interrupted time series studies, and applied
these as recommended by EPOC 2013: (i) the intervention is
independent of other changes, (ii) the shape of the intervention
effect is pre-specified, (iii) the intervention is unlikely to affect
data collection, (iv) knowledge of the allocated interventions is
adequately prevented during the study, (v) the outcome data are
incomplete, (vi) reporting is not selective, and (vii) there is no risk
of bias from other sources. Two review authors (DM, ARD) inde-
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pendently reached judgements about risk of bias using the guid-
ance provided by Higgins 2011 and EPOC 2013, and resolved
disagreements by discussion. A third review author (OO) dealt
with any disagreements that the two review authors could not re-
solve.
Measures of treatment effect
In order to standardise reporting of effect sizes, we re-analysed
data from individual studies to ensure that randomised trials and
controlled before-after studies could be reported as relative effects.
Interrupted time series were reported as change in level and change
in slope. We described the methods used for re-analysing and
presenting these data in Data synthesis.
Unit of analysis issues
We noted whether randomised trials randomised patients or
healthcare providers. If analysis did not allow for clustering of pa-
tients within healthcare providers, we recorded a unit of analysis
error, because such analyses tend to overestimate the precision of
the treatment effect. In the event of a unit of analysis error and
insufficient data to account for clustering, we did not report P
values or confidence intervals.
Dealing with missing data
In the event of important missing data, contacted the authors of
individual studies. As described inData synthesis, we electronically
extracted missing interrupted time series data that were presented
in graphs.
Assessment of heterogeneity
There were substantial differences between the policies and inter-
ventions described. There were also differences between the set-
tings, in terms of culture and health system delivery. Although
some studies evaluated similar interventions, there were still im-
portant clinical and methodological differences. As statistical tests
for heterogeneity lack power when few studies are included, we
elected not to calculate average effects across studies, or to estimate
statistical heterogeneity (Schroll 2011).
Assessment of reporting biases
We did not present funnel plots as we did not undertake a meta-
analysis and there were not more than 10 studies contributing to
any individual analysis (Higgins 2011).
Data synthesis
We followed theEPOCrecommendationswith regard to analysing
data from individual studies and meta-analysis (EPOC 2013). We
expressed the findings from controlled before-after studies as rel-
ative effects. To achieve this, we reported continuous variables as
relative change in outcome measures, adjusted for baseline dif-
ferences. We undertook absolute difference-in-difference analyses
that were adjusted for differences in the postintervention control
groupusing: ((postintervention intervention group - postinterven-
tion control group) - (preintervention intervention - pre-interven-
tion control))/postintervention control. For ease of comparison
with the findings of controlled before-after studies, we reported
the findings of randomised and non-randomised trials using the
same difference-in-difference analysis.
Interrupted time series are typically reported using regression anal-
ysis, such as autoregressive integrated moving average (ARIMA)
analysis. Pursuant to the EPOC recommendations, we present
outcomes along two dimensions: change in level and change in
slope (EPOC 2013). The former represents the immediate effect
of the intervention as measured by the difference between the fit-
ted value for the first post-intervention time point and the pre-
dicted outcome at the same point, based only on an extrapolation
of the pre-intervention slope. Change in slope is an expression of
any longer-term effect of the intervention. We decided to use a
similar method to the change in level, but a later follow-up period,
e.g. six months.
In the event that appropriate interrupted time series analyses were
not reported but that data were presented graphically, we read val-
ues from graphs using Plot Digitizer v2.6.8 (Huwaldt 2004). We
extracted ’actual’ data points from all studies and only planned to
use lines of best fit in the event that true points were not avail-
able. A segmented time series model (Y(t) = B0 + B1*preslope +
B2*postslope + B3* intervention + e(t)) was specified, in which
Y(t) was the outcome inmonth t. Preslope is a continuous variable
that indicates time from the beginning of the study until the end
of the pre-intervention phase, after which it was coded as a con-
stant. Postslope is assigned the value 0 until after the intervention
takes place, after which it is coded sequentially from 1 (i.e. 1, 2,
3). Intervention is assigned the value 0 pre-intervention and 1 in
the postintervention time period. In this model, B1 estimates the
pre-intervention slope, B2 the postintervention slope, and B3 the
change in level, i.e. the difference between the first postinterven-
tion time point and the extrapolated first postintervention time
point had the pre-intervention line continued into the postinter-
vention period. The difference in slope was determined using B2
- B1.
We reported effects at 3, 6, 9, 12, and 24 months postinterven-
tion when the data were available. Given the substantial degree of
clinical and methodological heterogeneity between the studies, we
presented the findings for each policy in a structured format, but
did not undertake a meta-analysis.
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Summary of findings
We summarised the findings of themain intervention comparisons
in a ’Summary of findings’ table to illustrate the certainty of the
evidence. One review author (DM) categorised the certainty of the
evidence as high,moderate, low, or very low, using the fiveGRADE
domains ( study limitations, consistency of effect, imprecision, in-
directness, and publication bias ( Guyatt 2011)). We undertook
this pursuant to Chapter 12 of the Cochrane Handbook for Sys-
tematic Reviews of Interventions and worksheets created by EPOC
(Higgins 2011; EPOC 2013). All other co-authors checked these
judgments, and resolved disagreements through discussion. When
ratings were up- or down-graded, we justified these decisions using
footnotes in Appendix 2 and Summary of findings for the main
comparison. Standardised statements for reporting effects and cer-
tainty of evidence were selected, based on theGRADE assessments
for each outcome, and used throughout the review (EPOC 2017).
The seven outcomes reported in Summary of findings for themain
comparison are:
• Changes in healthcare utilisation by consumers
• Changes in healthcare decisions taken by healthcare
providers (professionals and organisations)
• Changes in the healthcare utilisation decisions by
healthcare purchasers
• Changes in provider performance
• Changes in patient outcome
• Adverse effects
• Impact on equity
Subgroup analysis and investigation of heterogeneity
As described in Data synthesis, we presented the findings of indi-
vidual studies in a structured format rather than attempting meta-
analysis, given the substantial heterogeneity between the studies.
Therefore, it was not possible to undertake subgroup analyses.
Sensitivity analysis
In the absence of a formal meta-analysis, we did not undertake
any sensitivity analyses.
R E S U L T S
Description of studies
The included studies are summarised in Table 1 and described
fully in Characteristics of included studies. A number of studies
that narrowly failed to satisfy our selection criteria are described
in Characteristics of excluded studies.
Results of the search
The electronic searches for this update retrieved 5658 individual
items; a further 48 were identified from other sources, e.g. man-
ual searching of reference lists. We excluded 5656 items because
the titles and abstracts did not meet our inclusion criteria. We
retrieved the full-text versions of the remaining 50 articles; 38
of these did not satisfy the inclusion criteria; five with reasons,
see (Characteristics of excluded studies). Five of the remaining 16
articles reported separate analyses of a single cluster randomised
trial, and so we treated them as a single study for the purposes of
this review (Zhang 2016). Therefore, we included 12 studies in
the review. As described in Data synthesis, we did not undertake
formal meta-analyses due to substantial inter-study heterogeneity.
We presented the study flow chart in Figure 1 (Moher 1999).
Included studies
We included 12 studies that comprised more than 7570 providers
(e.g. professionals and organisations) and a further 3,333,386 clin-
ical encounters (e.g. patient referrals, prescriptions). There were
four cluster randomised trials (Farley 2002a; Tu 2009; Ikkersheim
2013; Zhang 2016), one cluster-non-randomised trial (Farley
2002b), six interrupted time series studies (Romano 2004; Jang
2011; Flett 2015; DeVore 2016; Joynt 2016; Liu 2017), and one
controlled before-after study (Rinke 2015). Eight were conducted
in the USA (Farley 2002a; Farley 2002b; Romano 2004; Flett
2015; Rinke 2015; DeVore 2016; Joynt 2016; Liu 2017), and one
each in Canada (Tu 2009), the Netherlands (Ikkersheim 2013),
Korea (Jang 2011), and China (Zhang 2016).
Three studies focused on changes in the healthcare utilisation de-
cisions of consumers (Farley 2002a; Farley 2002b; Romano 2004),
four of providers (Jang 2011; Ikkersheim 2013; Flett 2015; Zhang
2016), and none of purchasers. Two studies reported data on
changes to provider performance (Tu 2009; Rinke 2015), five on
patient outcomes (Tu 2009; Flett 2015;DeVore 2016; Joynt 2016;
Liu 2017), and none on staff morale. No study explicitly reported
adverse events as a separate outcome, or gave particular consider-
ation to effects on equitable health care.
Three US studies examined the effect of a single suite of interven-
tions (i.e. laws mandating public reporting of healthcare-associ-
ated infections in the United States), which were introduced by
some state legislatures between 2006 and 2009 (Flett 2015; Rinke
2015; Liu 2017). Liu 2017 examined the effect of mandatory re-
porting on central line-associated bloodstream infection rates in
adult intensive care units. They undertook an interrupted time
series study using data from hospitals contributing to the Na-
tional Healthcare Safety Network between 2006 and 2012. States
that did not introduce mandatory reporting were used to control
for secular trends through a difference-in-difference analysis. The
other two studies focused their analyses on healthcare-associated
infections in paediatric inpatients (Flett 2015; Rinke 2015). Rinke
2015 sought to determine whether mandatory central line-asso-
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ciated bloodstream infection public reporting was associated with
a reduction in a specific paediatric safety indicator (PDI12, i.e.
selected infections due to medical care), which is defined using di-
agnosis codes on hospital discharge. They undertook a controlled
before-after study using the Kids’ Inpatient Database, which is
one of a suite of administrative healthcare databases coordinated
by the Healthcare Cost and Utilization Project at the US Agency
for Healthcare Research and Quality. Flett 2015 did not exam-
ine patient outcomes, but aimed to test the hypothesis that clini-
cians in hospitals that are required to report central line-associated
bloodstream infections would modify their behaviour by sending
fewer blood culture tests or prescribing longer courses of antibi-
otics. They undertook an interrupted time series using data from
the Pediatric Health Information System, which is a collaborative
venture between children’s hospitals that is used for clinical audit
and quality improvement. The data were analysed using gener-
alised linear mixed-effects models with auto-correlated residuals to
compare central line-associated bloodstream infections adjusted
rate ratios before and after implementation of mandatory report-
ing laws.
Two US studies studied the effect of providing information about
plan performance on choice of insurance plan by new Medicaid
beneficiaries (Farley 2002a; Farley 2002b). Farley 2002a was a clus-
ter-randomised trial, using data from new Medicaid beneficiaries
in Iowa. Under Iowa Medicaid, new enrollees were automatically
assigned, by default, to one of four private health maintenance
organisations or theMedicaid primary care case management pro-
gramme. They were sent a packet of information about their spe-
cific health plan and benefits under Medicaid. The control group
received the standard packet of information and the intervention
group received this, plus an additional report that described the
performance of each health plan, along domains such as ’overall
health care rating’, and ’personal doctor rating’. The authors used
multinomial logistic regression to model the odds of new bene-
ficiaries electing to continue with or change their allocated plan.
In Farley 2002b, the same author team undertook a cluster-non-
randomised trial to evaluate the same performance reports on ben-
eficiary choice within the New Jersey Medicaid programme. The
study design was very similar to Farley 2002a, in terms of control
and intervention groups, although this was technically an non-
randomised trial, because participants were allocated according to
the last digit of their Medicaid case ID number. The objective
outcome measure reported was the effect of performance reports
on Medicaid beneficiary plan choices.
The other three US studies each examined the impact of different
public reporting initiatives on patient outcomes (Romano 2004;
DeVore 2016; Joynt 2016). Two used Medicare claims data, and
so confined their analyses to the Medicare population, i.e. those
aged 65 years or older (DeVore 2016; Joynt 2016). DeVore 2016
undertook an interrupted time series to study the effect on 30-
day re-admissions, of publicly reporting risk-adjusted hospital re-
admission rates for patients with selected conditions (acute my-
ocardial infarction, heart failure, and pneumonia) on the Hospital
Compare website. Joynt 2016 reported an interrupted time series
with a similar study design to DeVore 2016, but examined the
impact on mortality rates, of public reporting of mortality (for
patients with the same three selected conditions) on the Hospital
Compare website. They used hierarchical modelling to compare
30-day mortality in the pre- and postreporting periods. The final
US study presented an interrupted time series based on the Cal-
ifornia Hospital Outcomes Project in California and the Cardiac
Surgery Reporting System in New York (Romano 2004). This
study evaluated the effects of publishing report cards on trends in
hospital volumes for specific diagnoses, i.e. coronary artery bypass
surgery mortality in New York, and both acute myocardial infarc-
tion and postdiscectomy complications in California. The inter-
rupted time series examined hospital case volumes, determined
using administrative data sets in each state (the California Patient
Discharge Data Set and the New York Statewide Planning and
Research Cooperative System) before and after the publication of
reports that identified hospitals as performance outliers. These re-
ports were published by the California Hospital Outcomes Project
and the New York Cardiac Surgery Reporting System.
There were three cluster-randomised trials outside the US; one
each in Canada (Tu 2009), the Netherlands (Ikkersheim 2013),
and China (Zhang 2016). In Canada, Tu 2009 evaluated the pub-
lic release of performance data about 12 care quality indicators
for acute myocardial infarction and six for congestive heart failure
in 86 hospitals. Participating hospitals were randomised to either
early (January 2004) or delayed (September 2005) publication of
performance report cards. The performance data were provided to
individual hospitals, and then publicised both online and through
popular media, with coverage achieved through television, radio,
and newspapers. The outcomes reported by this study were any
change in hospital performance, measured using the 18 care qual-
ity indicators. The cluster-randomised trial in the Netherlands
randomised 26 GPs to receive either individualised hospital report
cards (65.4%), or to a control group (34.6%) that did not receive
this information (Ikkersheim 2013). The study then captured in-
dividual patient referrals (for breast cancer, cataract surgery, and
hip or knee replacement) to one of four hospitals in the region, us-
ing an electronic referral system. Zhang 2016 undertook a cluster-
randomised trial in Hubei Province, south central China. They
matched 20 primary care providers within a single city, based on
similar organisational characteristics. In this matched-pair cluster-
randomised trial, half the providers were randomised to public re-
porting of injection prescribing, by way of league tables that were
posted on outpatient bulletin boards. Performance data were also
disseminated to both local health authorities and the leaders of
hospitals in the intervention group. The outcomes were the per-
centage of prescriptions requiring antibiotics, percentage requir-
ing intravenous antibiotics, and the average expenditure per pre-
scription.
Finally, a single interrupted time series study was undertaken in
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Seoul, South Korea by Jang 2011. In this study, the intervention
was public release of data (online and in media releases) about
caesarean section rates for 1194 institutions across the country.
These rates were publicised as part of a series of public releases,
which were not described in detail. The outcome was change in
risk-adjusted institutional caesarean section rates over the whole
study period, and after each public release of data.
Excluded studies
In total, we excluded 38 studies after assessing full copies of the
papers. The main reasons for exclusion were: ineligible study de-
sign (24), interventions did not contain process measures, health
care outcomes, structure measures, consumer or patient experi-
ences, expert- or peer-assessed measures (8), no objective outcome
data were recorded or available for one or both arms (3), the study
was about hypothetical choices (3). We listed selected studies that
readers might reasonably have expected to find included in this
review in the ’Characteristics of excluded studies’ table.
Risk of bias in included studies
The included studies were rated on different risk of bias items
as appropriate for each study design (randomised trial, non-ran-
domised trial, controlled before-after, or interrupted time series).
We described this in Assessment of risk of bias in included studies,
but in summary, we rated randomised trials, non-randomised tri-
als, and controlled before-after studies using the same nine cri-
teria, and used seven criteria for interrupted time series studies.
We showed the results of these risk of bias assessments in the
’Characteristics of included studies’ tables and summarised them
in both Figure 2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item, presented as
percentages across all included studies. The blank spaces represent risk of bias criteria that were not
applicable to the study design.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study. The blank cells represent risk of bias criteria that were not applicable to the study design.
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Allocation
The extent of possible selection bias due to the random sequence
generation process was unclear in two studies, because the precise
method of random sequence generation was not described (Farley
2002a; Ikkersheim 2013). Two studies were at high risk, as Rinke
2015 was a controlled before-after study, and Farley 2002b was a
cluster-non-randomised trial, and so used a non-random method
of sequence generation. We judged risk of selection bias as low
for Zhang 2016 who ’flipped a coin to randomly assign’ paired
primary care institutions, and Tu 2009 who employed a dedicated
study statistician to implement a stratified randomisation process.
We made the same judgements for allocation concealment as for
random sequence generation, except for Zhang 2016, which was
judged to be at high risk for allocation concealment given their
use of a coin flip.
Blinding
Although hospitals and healthcare providers could not be blinded
to their allocated groups, individual participants were unlikely to
have been aware that a study was taking place. No study explicitly
contacted individual patients or members of the public to inform
them about the research question, intervention, or measured out-
comes. For this reason, two studies were considered to be at un-
clear risk, as it was not stated whether individuals in those trials
were informed that a study was taking place (Farley 2002a; Farley
2002b). Four studies were at high risk, because providers were
likely to know that a study was taking place, and it was not possi-
ble to blind them to their group allocation (Tu 2009; Ikkersheim
2013; Rinke 2015; Zhang 2016).
Incomplete outcome data
We judged 11/12 included studies to be at low risk of attrition bias,
because these studies based their outcomes on routinely collected
administrative data, e.g. electronic prescriptions or hospital refer-
rals. Only Tu 2009 was judged to be at high risk of bias, because
five randomised hospitals withdrew due to resource constraints;
one after randomisation and four during follow-up. Although only
a small proportion (5.8%) of the hospitals randomised in this clus-
ter-randomised trial withdrew, it is plausible that poorly perform-
ing institutions would be more likely to withdraw than those with
average or high performance.
Selective reporting
Only Tu 2009 registered a trial protocol with ClinicalTrials.gov
( NCT00187460) in advance of undertaking the study. All out-
comes described in this protocol were presented in the final report,
which also included all-cause mortality as an additional outcome.
Therefore, we judged it to be at low risk of reporting bias. Al-
though Zhang 2016 presented a trial protocol, this was published
in March 2015, eighteen months after the intervention began in
October 2013. None of the remaining ten studies registered a
protocol in advance of randomisation (randomised and non-ran-
domised trials) or data analysis (interrupted time series and con-
trolled before-after series).
Other potential sources of bias
As outlined in the ’Assessment of risk of bias in included studies’
section, the four cluster-randomised trials (Farley 2002a; Tu 2009;
Ikkersheim 2013; Zhang 2016), cluster-non-randomised trial
(Farley 2002b), and controlled before-after study (Rinke 2015),
were assessed for bias in terms of baseline characteristics, baseline
outcome measures, and protection against contamination. In ad-
dition, we assessed these sources of bias for the six interrupted time
series studies: intervention is independent of other changes, shape
of the intervention is prespecified, intervention is unlikely to affect
data collection, and knowledge of the allocated interventions is
adequately prevented during the study (Romano 2004; Jang 2011;
Flett 2015; DeVore 2016; Joynt 2016; Liu 2017).
Baseline characteristics
We considered four studies to be at low risk of bias for baseline
characteristics because the intervention and control groups were
shown to be similar (Tu 2009; Ikkersheim 2013; Rinke 2015;
Zhang 2016). Two studies did not report baseline characteristics,
and we considered them to be at unclear risk of bias (Farley 2002a;
Farley 2002b).
Baseline outcome measures
All six interrupted time series studies presented baseline out-
come measures that differed between the intervention and con-
trol groups. However, all six also used appropriate statistical tech-
niques, includingmultivariable regression (Farley 2002b;Tu 2009;
Ikkersheim 2013; Rinke 2015; Zhang 2016), and difference-in-
differences analyses (Tu 2009; Rinke 2015; Zhang 2016) to ac-
count for differences in baseline between the groups. They were
therefore all considered to be at low risk of bias from this source.
Protection against contamination
We judged three studies to be at low risk of contamination, ei-
ther because they randomisedhealthcare professionals (Ikkersheim
2013), or because their intervention was sent by post, and so un-
likely to reach individuals in the control group (Farley 2002a;
Farley 2002b).
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We assessed two studies to be at high risk. The authors of Tu 2009
stated that several hospitals in the delayed feedback group reported
that they also initiated quality improvement activities after be-
coming aware that performance measures were due to be released
publicly. As this was not quantified, it was difficult to determine
the degree to which hospitals in the control group modified their
activities in anticipation of having to publicly release performance
data. We also assessed Rinke 2015 at high risk because hospitals
in states that did not mandate healthcare-associated infection re-
porting might still have modified their practice, given that such
laws were being introduced elsewhere in the USA.
We judged Zhang 2016 to be at unclear risk, because no specific
efforts were taken to protect against contamination. However, it
is not certain that their intervention (posters on bulletin boards in
outpatient areas of intervention organisations) would necessarily
have influenced behaviour in control institutions.
Intervention independent of other changes
In three interrupted time series studies, it was unclear whether the
intervention occurred independently of other changes over time,
or whether the outcome was influenced by other confounding
variables and events during the study period (Romano 2004; Jang
2011; DeVore 2016). We judged the remaining three interrupted
time series studies to be at low risk of bias. In the two studies
that examined public reporting of healthcare-associated infections,
this was because they analysed data from a number of states that
introduced legislation at different times (Flett 2015; Liu 2017).
We judged Joynt 2016 to be at low risk, because they did not
demonstrate a substantial change in the postintervention period,
so this was unlikely to be attributable to other factors.
Shape of intervention effect prespecified
Two interrupted time series studies prespecified the shape of the
intervention effect, so we assessed both to be at low risk of bias
in this domain (Romano 2004; Jang 2011). The remaining four
interrupted time series studies did not, and we judged them to be
at high risk.
Knowledge of the allocated interventions adequately
prevented during the study
All six interrupted time series studies reported objective outcome
measures, so we judged them to be at low risk of bias for this
domain.
Intervention unlikely to affect data collection
The intervention was unlikely to affect data collection in any of
the six interrupted time series studies, as all were undertaken retro-
spectively, using routinely collected data. In all cases, the methods
of data collection were the same before and after the intervention.
Therefore, we judged all six studies to be at low risk of bias.
Effects of interventions
See: Summary of findings for the main comparison Public
reporting of performance data versus no public reporting
The studies included in this review used a wide range of differ-
ent interventions, which are described in the ’Characteristics of
included studies’ tables. We presented the effect sizes reported by
each outcome and study in Table 2, Table 3, Table 4, and Table 5,
together with the relative effects, for ease of comparison between
different study designs and outcome measures. We also provided
a ’Summary of findings’ table, together with our decisions on how
we determined levels of certainty (Summary of findings for the
main comparison; Appendix 2).
Primary outcomes
Changes in healthcare utilisation by consumers
This review provided an indication of the likely effect of pub-
lic release of performance data on healthcare utilisation by con-
sumers. There was low-certainty evidence from three studies that
public release of performance data may make little or no differ-
ence to long-term healthcare utilisation by consumers. Two stud-
ies included data from over 18,294 insurance beneficiaries (Farley
2002a; Farley 2002b), and it was unclear how many consumers
were analysed by Romano 2004.
There was low-certainty evidence from one study that public re-
lease of performance data can lead to small and transient effects on
healthcare utilisation behaviour by consumers (Romano 2004).
This study analysed hospital patient volumes following implemen-
tation of the California Hospital Outcomes Project, which classi-
fied acute hospitals as better, worse or neither better nor worse than
expected, based on the adjusted-mortality of patients with acute
myocardial infarction, or undergoingdiskectomy.They found that
hospitals, which were high performing for adjusted mortality from
acute myocardial infarction, received higher volumes of acute my-
ocardial infarction than expected in the third and fourth quarters
after publication of the California Hospital Outcomes Project, al-
though there was nomeasurable effect in the early period following
publication. Similarly, inconsistent trends were observed amongst
diskectomy patients; the only reported association was between
high performing (low complication) hospitals and volume of pa-
tients with lumbar diskectomy. However, this effect size was very
small (less than one additional patient per month per hospital),
and so may not have been an important effect. Performance data
from New York was released as part of the Cardiac Surgery Re-
porting System. Romano 2004 analysed Cardiac Surgery Report-
ing System data from New York, and found that high performing
(low mortality) hospitals received a higher number of cases in the
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month following publication of a report (74.5 actual cases versus
61.1 expected). In the six months following designation as a high
performance outlier, hospitals admitted 24 (22%) additional pa-
tients for coronary artery bypass surgery, and within two months
after designation as a low performance outlier, hospitals treated 11
(16%) fewer patients. However, all volume effects had disappeared
within three months of data publication.
There was low-certainty evidence that suggested that public release
of performance data might effect the behaviour of specific sub-
groups. For example, Farley 2002b reported that the subgroup of
enrollees who actually read the Consumer Assessment of Health-
care Providers and Systems report chose plans with higher stan-
dardised Consumer Assessment of Healthcare Providers and Sys-
tems ratings than those in the control group (2.58 versus 1.81, P
< 0.01). Similarly, Romano 2004 found that the only detectable
changes in hospital volume were among patients undergoing coro-
nary artery bypass grafting in New York, and this change was en-
tirely driven by patients who identified as ’white and other race’.
They did not find evidence that black or Hispanic patient volumes
were affected by designating a hospital as a high coronary artery
bypass graft mortality outlier.
It is possible that restrictions on patient choice might act as an
effect modifier (Aggarwal 2017; Moscelli 2017). However, the
interventions in Farley 2002a and Farley 2002b were presented as
’true’ choices, since new insurance beneficiaries should not have
been limited by concerns around cost and distance. Similarly,
Romano 2004 studied hospital choice amongst elective surgical
populations seeking treatment at hospitals within a single city.
Changes in healthcare decisions taken by healthcare
providers (professionals and organisations)
This review provides some indication of the likely effect of pub-
lic release of performance data on decision making by healthcare
professionals. There was low-certainty evidence from four studies
that public release of performance data may make little or no dif-
ference to decisions taken by healthcare professionals. These stud-
ies included three million births (Jang 2011), and 67 healthcare
providers (Ikkersheim 2013; Flett 2015; Zhang 2016).
Two studies reported modest effects on some outcomes.
Ikkersheim 2013 did not find any clear affect on referral patterns
following public release of data about cataract surgery, or hip and
knee replacement. However, there was a small effect on referrals
for breast cancer, with general practitioners in the intervention
group referring 1.0% more cases (P = 0.01) to hospitals per incre-
mental percentage point on the report card scale of medical effec-
tiveness. Similarly, Zhang 2016 found that the effect of display-
ing prescription performance data in outpatient areas varied across
outcomes and disease groups. Public release of performance data
did not change the number of prescriptions containing antibiotics
in the bronchitis group, two or more antibiotics in the gastritis
group, injections in the hypertension group, or antibiotic injec-
tions in the bronchitis and hypertension groups. Similarly, the av-
erage prescription cost did not change for patients with hyperten-
sion. However, public release of performance data did appear to
reduce prescriptions containing antibiotics for gastritis (interven-
tion effect -12.7%, P < 0.001), two or more antibiotics for gastritis
(-3.8%, P = 0.005), injections for gastritis (-10.6%, P < 0.001),
and antibiotic injections for gastritis (-10.7%, P < 0.001). Aver-
age antibiotic prescription cost fell for patients with bronchitis (-
7.9%, P < 0.001) and gastritis (-5.7%, P = 0.005). These mixed
findings were also complicated by evidence that public release of
prescribing data increased prescriptions containing antibiotics for
patients with hypertension (intervention effect 2.0%, P = 0.08),
and injections for bronchitis (2.0%, P = 0.012).
One study found that the first public release of hospital caesarean
section rate data may have slightly reduced the number of patients
undergoing this procedure (-0.8%, P < 0.01), and that this per-
sisted until the end of the study, 20 months later. However, fur-
ther public releases of data did not exhibit any further effect on
caesarean section rates (Jang 2011).
Finally, Flett 2015 didnot find any evidence thatmandatory public
reporting of central line-associated bloodstream infections had any
effect on blood culture testing or antibiotic utilisation in paediatric
and neonatal intensive care units in the United States.
Changes in the healthcare utilisation decisions of purchasers
We found no evidence on the effect of public release of perfor-
mance data on this outcome.
Changes in provider performance
This review provides some indication of the likely effect of public
release of performance data on healthcare provider performance.
There was low-certainty evidence from one study that public re-
lease of performance data may make little or no difference to ob-
jective measures of provider performance. Tu 2009 included data
from 82 healthcare providers.
Tu 2009 found that a media campaign and release of hospital per-
formance data online had no effect on 11 of 12 acute myocar-
dial infarction process-of-care quality indicators. The twelfth acute
myocardial infarction quality indicator (fibrinolytics given prior
to transfer to the Coronary Care Unit or Intensive Care Unit) in-
creased by 5.8% (P = 0.02), although no statistical correction was
made for multiple hypothesis testing. Similarly, public release of
performance data did not clearly effect five of six congestive heart
failure quality indicators, although the sixth (Angiotensin-Con-
verting Enzyme (ACE) inhibitor or Angiotensin Receptor Blocker
(ARB) for left ventricular dysfunction) increased by 5.9% (P =
0.02).Neither the acutemyocardial infarctionnor congestive heart
failure composite process-of-care quality indicators improved fol-
lowing the public release of performance data.
The main outcomes in two studies described above, are sometimes
considered evidence of provider performance (Jang 2011; Zhang
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2016). However, as these outcomes (caesarean section and antibi-
otic prescribing) may be appropriate clinical decisions, they are
not direct evidence of poor performance, so we have considered
them under ’Changes in healthcare decisions taken by healthcare
providers (professionals and organisations)’ instead of ’Provider
performance’.
Changes in patient outcome
Low-certainty evidence from five studies suggested that public
release of performance data may slightly improve patient out-
comes. We graded the certainty as low, because the evidence was
mixed, with two studies reporting improvements (Tu 2009; Liu
2017), and three finding no evidence of improved patient out-
comes (Rinke 2015; DeVore 2016; Joynt 2016). These five studies
included 7503 healthcare providers and 315,092 hospitalisations.
Two studies reported that patient outcomes were not changed by
publication of hospital-level qualitymetrics onHospital Compare,
which is a website run by the Centers for Medicare & Medicaid
Services. DeVore 2016 did not find any evidence that publica-
tion of hospital re-admission rates had an effect on 30-day re-ad-
missions for patients with myocardial infarction, heart failure, or
pneumonia. Similarly, Joynt 2016 reported a very small slowing in
a pre-existing trend (change 0.13% per quarter; 95% CI 0.12% to
0.14%) towards reduced 30-day mortality following publication
of mortality rates on Hospital Compare.
Rinke 2015 did not find any evidence that mandatory hospital
reporting of central line-associated blood stream infections had
any effect on the rate of paediatric central line-associated blood-
stream infections. However, Liu 2017 reported a 34% reduction
(incidence rate ratio 0.66, P < 0.001) in adult central line-asso-
ciated bloodstream infections after mandatory reporting, when
compared with the 25-month period before each state introduced
legislation. This discrepancy between the findings of Rinke 2015
and Liu 2017 might reflect a genuine difference in terms of impact
on children and adult central line-associated bloodstream infec-
tion rates. Importantly, both studies found that central line-asso-
ciated bloodstream infection rates declined across the USA dur-
ing their study period, including in states that did not introduce
mandatory reporting. It is unclear whether public release of per-
formance data in some states contributed to this national decline,
even within states that did not introduce mandatory reporting.
Tu 2009 found that public release of hospital performance data
online and through the media was associated with a 2.5% reduc-
tion in 30-day mortality (P = 0.045) for patients with acute my-
ocardial infarction, although no such effect was observed in pa-
tients with congestive heart failure.
Changes in staff morale
We found no evidence on the effect of public release of perfor-
mance data on this outcome.
Secondary outcomes
Unintended and adverse effects or harms
We found no evidence on the effect of public release of perfor-
mance data on this outcome.
Impact on equity
Low-certainty evidence from one study suggested that public re-
lease of performance data may have different effects on advantaged
and disadvantaged populations (Romano 2004). As described in
’Changes in healthcare utilisation by consumers’, this study re-
ported that patients who identified as white and other race in
New York might have been influenced by publicly released hospi-
tal mortality rates when choosing a hospital in which to undergo
coronary artery bypass grafting. However, this same effect was not
observed in black or Hispanic patients undergoing the same pro-
cedure at hospitals in New York.
Other outcome measures
Two studies reported on awareness, knowledge of performance
data, attitude, and cost data (Farley 2002b; Ikkersheim 2013).
Farley 2002b reported secondary outcomes as a result of a survey,
although this was disseminated using a 3:1 ratio, and the results
were further complicated by low response rates. Ikkersheim 2013
undertook semi-structured interviews with 17 GPs but these were
largely focused on the specific intervention (report cards) and the
findings were poorly reported. Therefore, we decided to exclude
these results, and did not report these outcomes.
D I S C U S S I O N
Summary of main results
Changes in healthcare utilisation by consumers
Changes in healthcare utilisation are one of the two key ways in
which public release of performance data might improve health-
care quality (Berwick 2003).However, only three studies addressed
the impact onhealthcare utilisationdecisions by consumers (Farley
2002a; Farley 2002b; Romano 2004). We judged that they pro-
vided low-certainty evidence of little or no effect. There were con-
sistent results from two studies that showed some consumers may
engage with published performance data, and change their health-
care choices accordingly; this group was too small to register an
effect in the population as a whole (Farley 2002b; Romano 2004).
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Changes in healthcare decisions taken by healthcare
providers (professionals and organisations)
There was low-certainty evidence with mixed findings from
four studies, which reported either modest effects (Jang 2011;
Ikkersheim 2013; Zhang 2016), or no effect (Flett 2015), on
healthcare decisions taken by healthcare providers. Two studies
found evidence that public release of performance data had mod-
est effects on some of the healthcare decisions taken by healthcare
providers, but not all of the decisions measured (Ikkersheim 2013;
Zhang 2016). One study found that the first public release of data
had a small but sustained effect on caesarean rates, but that sub-
sequent releases did not affect the rate any further (Jang 2011).
Changes in provider performance
There was low-certainty evidence from one study that informed
conclusions about the effect of public release of performance data
on provider performance. A single randomised trial addressed this
question, and found that 2/18 (11.1%) of measured processes ap-
peared to improve in the intervention hospitals (Tu 2009). How-
ever, as no correction was made for multiple hypothesis testing
(Bender 2001), this did not provide convincing evidence that
provider performance was affected by public release of perfor-
mance data.
Changes in patient outcome
Low-certainty evidence showed that five studies that included pa-
tient outcomes had inconsistent findings, with two reporting im-
provements (Tu 2009; Liu 2017), and three reporting no differ-
ence (Rinke 2015; DeVore 2016; Joynt 2016).
Impact on equity
Only one study undertook a subgroup analysis to identify dif-
ferential effects of public release of performance data (Romano
2004). Low-certainty evidence from one study reported that white
and other race patients, undergoing coronary artery bypass graft-
ing in New York, may have been influenced by publicly released
mortality rates. However, this finding was not reproduced among
black and Hispanic patients. Although Farley 2002b did not study
equity directly, their finding that only consumers who read the
Consumer Assessment of Healthcare Providers and Systems report
were influenced, raises the possibility that some groups (e.g. those
with greater rates of literacy) might be preferentially influenced by
public release of performance data.
Other outcomes
There were no studies that considered the effect of public release
of performance data on changes in the healthcare utilisation de-
cisions of purchasers, changes in staff morale, or adverse effects.
Two studies reported on awareness, knowledge of performance
data, attitude, and cost data but we did not include the data due
to concerns about reporting and high attrition bias.
Overall completeness and applicability of
evidence
There are many systems around the world that include public
release of performance data. However, only a small proportion
were represented in this review, so it is likely that most have either
not been evaluated, or were subject only to low-quality studies.
It is notable that some interventions have been evaluated more
robustly than others, with two studies in this review considering
the Centers for Medicare & Medicaid Services website Hospital
Care (DeVore 2016; Joynt 2016), and three, the introduction of
state-based mandatory reporting of central line-associated blood
stream infections (Flett 2015; Rinke 2015; Liu 2017). Similarly,
the majority of the studies included in this review (9/12, 75%)
were based in North America, with no representation from South
America, Africa, or Australasia. Therefore, it is likely that a small
number of initiatives have attracted a disproportionate number of
studies, and there is clearly work that needs to be done to robustly
evaluate similar interventions in other settings. There was also
insufficient evidence to draw any conclusions about the healthcare
utilisation decisions of purchasers, staff morale, or adverse effects.
The applicability of the evidence was also limited by considerable
heterogeneity in interventions. For example, it was possible that
the freedom of patients to choose healthcare providers was cur-
tailed in some cases, which might have acted as an effect modifier
that explains some of the differences in findings between included
studies. However, only three studies included interventions that
might lead to improved consumer selection, and consumer choice
would not obviously have been restricted by considerations around
distance and cost (Farley 2002a; Farley 2002b; Romano 2004).
These studies suggested that those engagingwith publicly reported
performance data (Farley 2002b), and those from privileged back-
grounds (Romano 2004), might be more likely to modify their
choice of healthcare provider. This raises the possibility that lack
of education and health literacy might restrict patient choice, and
act as an effect modifier in some cases.
The three studies that took place in the USA involved only a small
proportion of the numerous major reporting systems available.
We included one new study from Canada, which was published
after the latest systematic reviews by Fung 2008, Shekelle 2008,
and Faber 2009 (Tu 2009). We excluded many of the more recent
studies, because they did not have a rigorous study design, or did
not report the defined primary outcome measures. The studies we
included evaluated interventions that used data that might have
been originally collected for a purpose other than influencing be-
haviour or improving outcomes. It is possible that custom-made
interventions, using data collected for the specific purpose of in-
fluencing behaviour or improving outcomes, would have a greater
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impact. However, the lack of such interventions in the literature
highlighted the fact that their delivery may be excessively resource
intensive, and that future initiatives aimed at public release of per-
formance data will continue to draw on data initially collected for
a different purpose.
Despite evidence that secondary outcome measures (e.g. aware-
ness, attitude, knowledge of performance data) are crucial, since
public reporting can only change behaviour if the target popula-
tion (healthcare consumers, providers, or purchasers of care) un-
derstands the information, these measures were lacking in the in-
cluded studies (Hibbard 2010). Therefore, it was difficult to ex-
plain the lack of effect. For example, Faber 2009 found that the ef-
fect of performance data was higher for those who understand the
information, which might be consistent with the evidence from
Farley 2002b. Damman 2011 showed that comparative perfor-
mance information was complex, and consumers had difficulties
in interpreting and using performance data. However, it is notable
that this review did not find that healthcare providers (who might
be in a better position to interpret such data) were necessarily in-
fluenced more than consumers.
Certainty of the evidence
We deemed the certainty of the evidence that examined the effect
of public release of performance data on a number of outcomes to
be low. These outcomes were:
• Changes in healthcare utilisation by consumers;
• Changes in healthcare utilisation by providers
(organisations and professionals); and
• Changes in patient outcome.
Only 4/12 included studies (33.3%) were randomised trials, so
the evidence for these outcomes was partly informed by non-ran-
domised study designs. However, the use of EPOC study design
criteria ensured that all included observational studies took con-
siderable steps to minimise the risk of bias (EPOC 2013). There
was also considerable heterogeneity in the settings, outcomes, and
modes of public release, and inconsistent effects reported between
studies.
We also judged the certainty of the evidence that examined the
effect on changes in provider performance to be low. Although
this outcome was informed by a single randomised trial, we had
concerns about risk of bias in the following items: (1) allocation
concealment, (2) adequate blinding of participants, personnel and
outcome assessors, and (3) protection against contamination (Tu
2009). It is also uncertain whether the findings of a single ran-
domised trial, in a narrowly defined patient group, within one re-
gion of Canada, can be generalised to other settings.
Due to lack of evidence, we were unable to draw any conclusions
about the following primary outcomes:
• Changes in the healthcare utilisation decisions of
purchasers;
• Changes in staff morale.
In terms of secondary outcomes, there were no studies that set
out to consider adverse effects or harms. We deemed the evidence
for any potential impact on equity to be low, as it was based on
a subgroup analysis from a single interrupted time series study
(Romano 2004).
Potential biases in the review process
Although our search was comprehensive, we could not exclude the
possibility of having missed relevant studies. However, we min-
imised this risk by asking an Information Specialist to help de-
sign and implement the search strategy, and ensured that two re-
view authors independently examined all items retrieved from our
search. We also ensured that data extraction and ’Risk of bias’ as-
sessments were independently undertaken by two review authors.
Although the GRADE assessments were determined by a single
author (DM), these were checked by all review authors, and dis-
agreements resolved through discussion. These steps ensured that
potential biases in the review processes were mitigated as much as
possible. However, this stringent approach to study collection also
meant excluding most of the studies that have evaluated public
release of performance data in other settings, and using a range of
study designs. It was possible that this approach biased our review
against settings that were less likely to deliver studies that satisfied
the EPOC inclusion criteria, and this might have accounted for
the over-representation of studies from North America, Europe,
and Asia. It might also have led to the exclusion of studies (e.g.
those utilising qualitative designs) that contained important in-
formation about the impact of public release of performance data.
However, it was necessary to limit our review to studies that were
at the lowest possible risk of bias, to maximise the certainty of its
findings. There may nevertheless be scope for future reviews to
synthesise evidence from studies using a broader range of designs.
Agreements and disagreements with other
studies or reviews
Our systematic literature search and a further PubMed search of
studies citing an earlier versionof this review (Ketelaar 2011), iden-
tified three relevant systematic reviews (Fung 2008; Faber 2009;
Campanella 2016). Our review agreed with these earlier publica-
tions that previous studies were limited by risk of bias, inconsistent
findings, and heterogeneity of interventions, healthcare settings,
and outcomes.
Faber 2009 considered public release of performance data on con-
sumer choice, and concluded that there was only evidence to sup-
port an effect on the small subgroup of participants that actively
engaged with the published performance data. This was consistent
with our findings, and those of Fung 2008.
Campanella 2016 attempted ameta-analysis of data from ten stud-
ies, and reported improved mortality (risk ratio 0.85, 95% confi-
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dence interval 0.79 to 0.92). However, this finding was reported
in the context of very high heterogeneity (P < 0.0001; I² = 100%).
The authors limited their meta-analysis to studies that reported
sufficient data, and excluded those with inappropriate study de-
signs, or those that were at high risk of bias. Our review only con-
sidered studies that proffered the highest certainty of evidence, and
did not consider a meta-analysis appropriate in view of the con-
siderable degree of heterogeneity between studies (see Assessment
of heterogeneity). Instead, our findings were consistent with those
of Fung 2008, which concluded that “studies of the effect of pub-
lic reporting on outcomes provide mixed signals, and the useful-
ness of public reporting in improving patient safety and patient-
centeredness remains unknown, because few studies assessed these
end points”.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The existing evidence base on the effects of public release of per-
formance data on changing behaviour of healthcare decision mak-
ers was inadequate to directly inform practice.
Implications for research
In order to understand the effectiveness of the public release of
performance data, we need more longitudinal studies with robust
evaluation designs. In particular, the evidence base would bene-
fit from more studies that consider whether public release of per-
formance data can improve patient outcomes, rather than simply
healthcare processes. In this review, only one of the included stud-
ies reported data on patient outcomes (Tu 2009). Further work
should also specifically consider whether public release of perfor-
mance data might result in adverse effects or harms.
Unfortunately, most studies were unable to guarantee that dissem-
inated performance data actually reached its intended audience,
i.e. that lack of effect was not simply a result of failed exposure
to the intervention. Importantly, Farley 2002b reported evidence
to suggest that the subgroup of patients that read the reports sent
by post were influenced when choosing a health insurance pro-
gramme. Therefore, future studies should consider carefully how
they might maximise the number of people exposed to their inter-
vention, and whether this can be quantified. However, the effect
of public release of performance information in the ’real world’ is
likely to be limited by difficulties in reaching its intended audi-
ence (Hibbard 2007; Damman 2010; Aggarwal 2017; Canaway
2017; Moscelli 2017; Canaway 2018; Greenhalgh 2018). There-
fore, the need to ensure that performance data reach those who
are intended to be influenced, needs to be balanced against the
risk of reducing study validity by creating artificial conditions that
cannot be replicated when the intervention is used in practice.
Berwick’s model suggests that public release of performance data
may improve quality of care by means of a pathway of change
or selection (Berwick 2003). The studies we included focused ex-
clusively on either one or the other of these pathways. In addi-
tion, one assumption underlying public release of performance
data is that provider choice is a rational decision, i.e. consumers
prefer the healthcare provider or health plan that is rated as the
best. However, there is little evidence to confirm this assumption
(Faber 2009; Kolstad 2009), although a number of other factors
are known to influence consumer choice, e.g. established relation-
ships with local physicians, health plans (Schwartz 2005; Hibbard
2009), hospitals, distance, and opinions of friends, and family
(Harris 2008; The King’s Fund 2010). Similarly, Ikkersheim 2013
found that decisions taken by healthcare professionals were often
informed by their personal preferences, experience of, and com-
munication with other providers, and personal relationships with
other professionals. These factors influenced hospital referral deci-
sions evenwhen professionals were provided with objective perfor-
mance data. Future studiesmaywish to consider themechanism(s)
by which public release of performance data can effect change, as
well as whether such changes can be demonstrated empirically.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
DeVore 2016
Methods Design: ITS
Country: USA
Care setting: acute hospitals
Duration: 1 July 2006 to 30 June 2012
Dataset: 5% nationally representative sample of Medicare beneficiaries
Total participants: 315,092 hospitalisations
Unit of analysis: individual hospitalisations; accounted for clustering within hospitals
Data analysis: regression models
Participants Inclusion criteria: all patients enrolled with Medicare, i.e. predominantly those aged
65 years or older
Hospitals: more than 4,100 hospitals in the USA
Participants: 315,092: 37,829 acute myocardial infarction (16.0%), 100,189 heart fail-
ure (42.5%), 17,907 diabetes (7.6%), 80,091 chronic obstructive pulmonary disease
(33.9%)
Interventions Intervention: public reporting of risk-standardised hospital readmission rates on a public
website, Hospital Compare
Duration: June 2009 until the study end date in 2012
Deliverer:Centers forMedicare &Medicaid Services (CMS), USDepartment of Health
and Human Services
Funding: CMS (federal government funding)
Outcomes Main outcome
• 30-day post-discharge re-admission to hospital
Secondary outcomes
• 30-day post-discharge outpatients visits
• 30-day post-discharge emergency department visits
• 30-day post discharge observation stays without readmission
Notes Abbreviations: Interrupted Time Series (ITS) study
Risk of bias
Bias Authors’ judgement Support for judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data available for all patients
Selective reporting (reporting bias) Low risk All outcomes and results outlined in the
Method section were reported in tables,
text, or both
Other bias Low risk No additional biases identified
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DeVore 2016 (Continued)
Intervention is independent of other
changes? (ITS)
Unclear risk did not state whether there were other con-
founding events that might have changed
performance over time
Shape of intervention effect pre-specified?
(ITS)
High risk Shape of intervention effect not pre-speci-
fied
Knowledge of the interventions adequately
prevented during the study? (ITS)
Low risk Individuals would not have been aware of
the study, as this was performed retrospec-
tively, using the Medicare data set
Intervention unlikely to affect / bias data
collection? (ITS)
Low risk Routinely collected administrative data,
and so data collection was unlikely to be
biased by the intervention
Farley 2002a
Methods Design: cRT
Country: USA (Iowa)
Care setting: insurance plan beneficiaries in the community
Duration: February to May 2000
Dataset: data provided by the Iowa Medicaid office
Total participants: 13,077
Unit of allocation: household units
Unit of analysis: individual Medicaid beneficiaries; accounted for clustering of benefi-
ciaries within household units
Sample size calculation: not reported; statistical significance was assessed at the 0.05
level
Data analysis: multinomial logistic regression to model the outcomes (1) stayed in
assigned HMO, (2) switched to another HMO, or (3) switched to MediPass
Participants Inclusion criteria: all new cases (i.e. household units) newly eligible to participate in
Iowa Medicaid
Participants: 13,077 new beneficiaries in 7016 cases with 6515 beneficiaries in the
control group and 6562 in the intervention group
Health plans: two HMOs under contract with the Medicaid programme and 1 primary
care case management plan (MediPass). One HMO scored more highly on the publicly
reported performance measures than the other
Interventions Intervention: standard enrolment materials and Consumer Assessment of Healthcare
Providers and Systems (CAHPS) report delivered by personal mail
Control: standard enrolment materials delivered by personal mail
Duration: February to May 2000
Deliverer: the Iowa Medicaid office posted beneficiaries a packet health plan enrolment
materials that included items, such as a plan enrolment form and the CAHPS report for
the intervention group
Funding: co-operative agreement 5U18HS09204-05; the Agency for Healthcare Re-
search and Quality and the Center for Medicare and Medicare Services
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Farley 2002a (Continued)
Outcomes Main outcome
• decision to remain with allocated HMO, switch HMO, or switch to MediPass
Notes The star charts in the CAHPS report were based on each HMO’s performance. The bar
charts included 3 charts with ratings of the health plan, health care, and personal doctor.
Five charts were included by the providers or health plan
Abbreviations: cluster randomised trial (cRT); healthmaintenance organization (HMO)
; Consumer Assessment of Healthcare Providers and Systems (CAHPs)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The new cases enrolled during the study
period were randomly assigned to an ex-
perimental or control group. This random
assignment was independent of case size,
county of residence, and initial plan assign-
ment
Allocation concealment (selection bias) Unclear risk The new cases enrolled during the study
period were randomly assigned to an exper-
imental or control group
Adequate blinding of participants, person-
nel and outcome assessors?
Unclear risk did not state whether or not participants
knew that they were part of a study and
so had been allocated to an intervention or
control group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: ’Medicaid office supplied us with
data files for the full sample of new benefi-
ciaries’
Selective reporting (reporting bias) Low risk All outcomes and results outlined in the
Method section were reported in tables,
text, or both
Baseline characteristics similar? Unclear risk Did not explicitly describe baseline charac-
teristics, although attempted to take these
into account when determining risk-ad-
justed outcomes
Baseline outcomes similar? Low risk Did not explicitly describe baseline out-
comes, but accounted for differences ap-
propriately using multinomial logistic re-
gression
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Farley 2002a (Continued)
Protection against contamination Low risk No specific safeguards against contamina-
tion, but reports were sent by post, so it was
unlikely that the control group received the
intervention
Other bias Low risk No additional biases identified
Farley 2002b
Methods Design: cNRT (non-randomised as participants allocated based on their Medicaid case
ID number)
Country: USA (New Jersey)
Care setting: insurance plan beneficiaries in the community
Duration: March to October 1998
Dataset: data provided by the New Jersey Medicaid office
Total participants: 5217
Unit of allocation: household units
Unit of analysis: individual Medicaid beneficiaries; did not account for clustering of
beneficiaries within household units
Sample size calculation: not reported; statistical significance was assessed at the 0.05
level
Data analysis: multivariable logistic regression, using enrolment with the dominant
Healthcare Maintenance Organisation (HMO), despite this being shown to perform
poorly by the publicly released performance data
Participants Inclusion criteria: all new cases (i.e. household units) newly eligible to participate in
Iowa Medicaid
Participants: 5217 new beneficiaries with 2568 in the control group and 2649 in the
intervention group
Health plans: the Medicaid program has a form of mandatory (auto-assignment) vol-
untary managed care programme, which includes one or more HMOs or (sometimes) a
primary care case management plan. New enrollees have an option to switch programme
around the time of enrolment
Interventions Intervention: standard enrolment materials and Consumer Assessment of Healthcare
Providers and Systems (CAHPS) report delivered by personal mail
Control: standard enrolment materials delivered by personal mail
Duration: 25 March to 15 April 1998
Deliverer: the New Jersey Medicaid office published a 7-page brochure (“Choosing an
HMO”) that compared the Medicaid HMO consumer ratings and experiences reported
in the CAHPS survey
Funding: co-operative agreement 5U18HS09204-05; the Agency for Healthcare Re-
search and Quality and the Center for Medicare and Medicare Services
Outcomes Main outcome
• decision to remain with the dominant HM
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Farley 2002b (Continued)
Notes The star charts in CAHPS report were based on a HMO’s performance compared to
the average in every county of residence. The counts ranged from 20 to 29 stars. The
resulting standardised CAHPS ratings ranged from -8.40 (well below the average) to 6.
26 (well above the county average)
Abbreviations: cluster non-randomised trial (cNRT); Consumer Assessment of Health-
care Providers and Systems (CAHPs)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: ’Based on whether the last digit of
the case ID was odd or even, half the cases
were randomly assigned to an experimental
group and half were assigned to a control
group’
Allocation concealment (selection bias) High risk Allocation concealment was based on case
IDnumber, therefore research investigators
enrolling participants could possibly fore-
see assignment
Adequate blinding of participants, person-
nel and outcome assessors?
Unclear risk Not stated whether or not participants
knew that they were part of a study and
so had been allocated to an intervention or
control group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: ’The analysis of the overall effects
of CAHPS included the entire April 1998
sample of enrollees, and is therefore not
subject to non-response bias’
Selective reporting (reporting bias) Low risk All outcomes and results outlined in the
Method section were reported in tables,
text, or both
Baseline characteristics similar? Unclear risk Did not explicitly describe baseline charac-
teristics, although attempted to take these
into account when determining risk-ad-
justed outcomes
Baseline outcomes similar? Low risk Did not explicitly describe baseline out-
comes, but accounted for differences ap-
propriately using multinomial logistic re-
gression
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Farley 2002b (Continued)
Protection against contamination Low risk No specific safeguards against contamina-
tion, but reports were sent by post and so
it was unlikely that the control group re-
ceived the intervention
Other bias Low risk No additional biases identified
Flett 2015
Methods Design: ITS (with non-intervention control hospitals)
Country: USA
Care setting: paediatric and neonatal intensive care units
Duration: 2004 to 2012
Dataset: PHIS
Total participants: 21 acute hospitals
Unit of analysis: individual hospitals; accounted for clustering within hospitals
Data analysis: generalised linear mixed-effects models with auto-correlated residuals
Participants Inclusion criteria: children’s hospitals in US states that submitted data to the PHIS
Hospitals: 17 hospitals in 9 states that introduced public reporting of CLABSI rates,
and 4 hospitals in 4 states without public reporting. Minimal data provided about the
number or characteristics of individual patients treated within these hospitals
Interventions Intervention: state-basedmandatory public reporting of healthcare-associated infections
Duration: public reporting introduced between July 2005 and April 2010 (depending
on state) and lagged behind legislation by 6 to 27 months
Deliverer: individual state legislatures
Funding: unclear
Outcomes Main outcomes
• blood cultures per 1000 patient days
• number of antibiotic days per 1000 patient days
Notes Abbreviations: Interrupted Time Series (ITS) study; Paediatric Health Information Sys-
tem (PHIS); central line-associated blood stream infection (CLABSI)
Risk of bias
Bias Authors’ judgement Support for judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data for all included hospitals,
except for one that was excluded because of
excessive missing data
Selective reporting (reporting bias) Low risk All outcomes and results outlined in the
Method section are reported in tables, text,
or both
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Flett 2015 (Continued)
Other bias Unclear risk No additional biases identified
Intervention is independent of other
changes? (ITS)
Low risk Not stated whether there were other con-
founding events that might have changed
performance over time. However, this was
unlikely overall, as each state implemented
mandatory reporting at different stages and
using different regulatory mechanisms
Shape of intervention effect pre-specified?
(ITS)
High risk Shape of intervention effect not prespeci-
fied
Knowledge of the interventions adequately
prevented during the study? (ITS)
Low risk Individuals would not have been aware of
the study as this was performed retrospec-
tively, using a clinical registry
Intervention unlikely to affect / bias data
collection? (ITS)
Low risk Routinely collected clinical data, so data
collection was unlikely to be biased by the
intervention
Ikkersheim 2013
Methods Design: cRT
Country: the Netherlands (Eindhoven)
Care setting: primary care
Duration: 2009 to 2010
Dataset: prospective data collection from GPs
Total participants: 26 GPs (2:1 randomisation to intervention)
Unit of allocation: individual GPs
Unit of analysis: individual GPs; accounted for clustering of GPs within practices
Sample size calculation: not reported; statistical significance was assessed at the 0.05
level
Data analysis:multivariable logistic regression using a difference-in-difference approach
Participants Inclusion criteria: all GPs within the Eindhoven region
Participants: 26 GPs, with 17 in the intervention group and 9 in the control group
Participant characteristics:male 41% (intervention) versus 44% (control), urban 35%
(intervention) versus 33% (control)
Interventions Intervention: report cards sent by post toGPs that included a variety of quality indicators
that depended on the specific condition (breast cancer, cataract surgery, hip or knee
replacement)
Control: no report cards distributed to control GPs
Duration: no details provided
Deliverer: research team
Funding: the Dutch organisation for health research and development, ZonMw
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Ikkersheim 2013 (Continued)
Outcomes Main outcome
• choice of hospital when making patient referrals
Notes Abbreviations: cluster-randomised trial (cRT); general practitioner (GP)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation unclear
Allocation concealment (selection bias) Unclear risk No statement about allocation conceal-
ment
Adequate blinding of participants, person-
nel and outcome assessors?
High risk No blinding of participants or personnel;
the outcomes measured GP behaviour (i.e.
referral patterns); individual GPs were not
blinded to the group allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data from all participating GPs included
Selective reporting (reporting bias) Low risk All outcomes and results outlined in the
Method section were reported in tables,
text, or both
Baseline characteristics similar? Low risk Some baseline characteristics described
(health professional sex andurban location)
, which suggested that the groups were bal-
anced
Baseline outcomes similar? Low risk Baseline outcomes varied between hospi-
tals, although multivariable logistic regres-
sion was used to adjust for baseline differ-
ences
Protection against contamination Low risk No specific safeguards against contamina-
tion, although it was unlikely that GPs
shared hospital report cards amongst them-
selves when they knew these were the sub-
ject of a trial
Other bias Low risk No additional biases identified
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Jang 2011
Methods Design: ITS
Country: South Korea
Care setting: paediatric and neonatal intensive care units
Duration: 2003 to 2007
Dataset: HIRA National Quality Improvement database
Total participants: not stated; approximately 3,000,000 live births would have been
included between January 2003 and May 2007 according to data provided by Chung
2014
Unit of analysis: individual hospitals
Data analysis: time series ARIMA analysis
Participants Inclusion criteria: all hospitals performing 100 or more deliveries per year
Hospital types: tertiary care hospitals (3.6%), general hospitals (13.1%), hospital (13.
1%), clinic (35.4%)
Hospital regions: capital city (4.9%), metropolis (31.7%), satellite city (22.5%), city
(24.5%), rural (16.3%)
Hospital ownership: public (3.2%), non-public (96.8%)
Hospital deliveries (per year): > 700 (4.3%), 201 to 700 (26.4%), < 200 (69.4%)
Interventions Intervention: repeated public release of information (online, press releases) on hospital
caesarean rates
Duration: four distinct interventions (September 2005, January 2006, September 2006,
January 2007)
Deliverer: HIRA, South Korea
Funding: HIRA, South Korea
Outcomes Main outcome
• risk-adjusted institutional caesarean section rates
Notes Abbreviations: Health Insurance Review & Assessment Service (HIRA); Autoregressive
Integrated Moving Average (ARIMA)
Risk of bias
Bias Authors’ judgement Support for judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data available for all patients
Selective reporting (reporting bias) Low risk All outcomes and results outlined in the
Method section were reported in tables,
text, or both
Other bias Low risk No additional biases identified
Intervention is independent of other
changes? (ITS)
Unclear risk Not stated whether there were other con-
founding events that might have changed
performance over time
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Jang 2011 (Continued)
Shape of intervention effect pre-specified?
(ITS)
Low risk The authors pre-specified that RPR would
decrease and that cesarean section rates of
institutions with higher cesarean section
rates in the period before RPR would de-
crease further after RPR than those with
lower starting rates
Knowledge of the interventions adequately
prevented during the study? (ITS)
Low risk Did not state explicitly that those respon-
sible for data collection were informed that
the publication of performance data was
part of a study
Intervention unlikely to affect / bias data
collection? (ITS)
Low risk Routinely collected administrative data
that were collected independently of the in-
dividuals at whom the public release of per-
formance data were directed
Joynt 2016
Methods Design: ITS
Country: USA
Care setting: acute hospitals
Duration: January 2005 to November 2012
Dataset: Medicare inpatient files
Total participants: 20,707,266
Unit of analysis: individual patients; accounted for clustering within hospitals
Data analysis: multivariable logistic regression
Participants Inclusion criteria: all Medicare fee-for-service enrollees hospitalised with any of the 15
most common non-surgical discharge diagnoses. Medicare is predominantly composed
of patients aged 65 years or older.
Hospitals: 3970 hospitals
Hospital types: 6.8% major teaching hospital, 18.3% minor teaching hospital, 74.9%
non-teaching
Hospital size: 42.7% small, 46.3% medium, 11.0% large
Hospital ownership: 15% for-profit, 62.8% non-profit, 22.1% public
Patients: 20,707,266
Patient characteristics: mean age 79 years, 41% male
Interventions Intervention: Public release of hospital performance data (using 30-day mortality),
published on a publicly accessible website. The intervention was the addition of 30-
day mortality to publicly accessible hospital performance data in 2008. In the pre-
intervention period, hospital performance data were available in the same format, but
was limited to process metrics.
Duration: 4 years
Deliverer: Hospital Compare, which is maintained by the CMS
Funding: CMS
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Joynt 2016 (Continued)
Outcomes Main outcome
• risk-adjusted 30-day mortality
Notes Abbreviations: interrupted time series (ITS) study; Centers for Medicare & Medicaid
Services (CMS)
Risk of bias
Bias Authors’ judgement Support for judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data from all participating hospitals in-
cluded
Selective reporting (reporting bias) Low risk All outcomes and results outlined in the
Method section were reported in tables,
text, or both
Other bias Low risk No additional biases identified
Intervention is independent of other
changes? (ITS)
Low risk Not stated whether there were other con-
founding events that might have changed
performance over time. However, this was
unlikely, given that this study identified few
changes in outcome after the intervention
Shape of intervention effect pre-specified?
(ITS)
High risk Shape of intervention effect not prespeci-
fied
Knowledge of the interventions adequately
prevented during the study? (ITS)
Low risk Individuals would not have been aware of
the study, as this was performed using rou-
tinely collected administrative data
Intervention unlikely to affect / bias data
collection? (ITS)
Low risk Routinely collected administrative data, so
data collection was unlikely to be biased by
the intervention
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Liu 2017
Methods Design: ITS (with non-intervention control hospitals)
Country: USA
Care setting: adult ICUs
Duration: 2006 to 2012
Dataset: CDC NHSN dataset
Total participants: 244 acute hospitals
Unit of analysis: individual CLABSIs; accounted for clustering within hospitals
Data analysis:multi-variable regression, using a difference-in-difference approach from
hospitals in states that did not introduce mandatory reporting
Participants Inclusion criteria: all non-VA acute hospitals enrolled in the NHSN were eligible to
participate
Hospitals: 244 hospitals with 475 ICUs
Hospital teaching hospital status: control (469 ICU days, 59.1%), intervention (844,
76.2%)
Intensive care unit bed size > 30: control (45 ICU days, 5.7%), intervention (68, 6.
1%)
Number of patient days per year: control (mean 1384.1, standard deviation (SD) 2152.
0), intervention (1855.4, SD 1447.6)
Patient characteristics: no substantial case mix data provided
Interventions Intervention: mandatory public reporting of healthcare-associated infections
Duration: variable, depending on the state being studied
Deliverer: individual state legislatures
Funding: unclear
Outcomes Main outcome
• CLABSIs per 1000 patient days
Notes Abbreviations: interrupted time series (ITS study); intensive care unit (ICU); Centers for
Disease Control and Prevention (CDC); National Healthcare Safety Network (NHSN)
, central line-associated blood stream infection (CLABSI); Veterans Affairs (VA)
Risk of bias
Bias Authors’ judgement Support for judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data for all eligible hospitals in-
cluded
Selective reporting (reporting bias) Low risk All outcomes and results outlined in the
Method section were reported in tables,
text, or both
Other bias Low risk No additional biases identified
Intervention is independent of other
changes? (ITS)
Low risk Not stated whether there were other con-
founding events that might have changed
performance over time. However, this was
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unlikely overall, as each state implemented
mandatory reporting at different stages,
and using different regulatory mechanisms
Shape of intervention effect pre-specified?
(ITS)
High risk Shape of intervention not prespecified
Knowledge of the interventions adequately
prevented during the study? (ITS)
Low risk Individuals would not have been aware of
the study as this was performed retrospec-
tively, using administrative data
Intervention unlikely to affect / bias data
collection? (ITS)
Low risk Routinely collected clinical data, so data
collection was unlikely to be biased by the
intervention
Rinke 2015
Methods Design: CBA
Country: USA
Care setting: acute hospitals
Duration: 2000 to 2009
Dataset: HCUP Kids’ Inpatient Database
Total participants: 4,705,857 paediatric hospital discharges
Unit of allocation: paediatric hospital discharges
Unit of analysis: paediatric hospital discharges; accounted for clustering of discharges
within hospitals and states
Sample size calculation: not reported; statistical significance was assessed at the 0.05
level
Data analysis: multivariable logistic regression
Participants Inclusion criteria: all paediatric hospital discharges eligible for PDI2 (i.e. length of stay
2 or more days) in a state that was categorised as ’never reporters’ (18 states), ’2006
reporters’ (2 states), or ’2009 reporters’ (7 states)
Hospitals: 3207; 2066 of which were ’never reporters’, 135 were ’2006 reporters’, and
1006 were ’2009 reporters’
Hospital teaching status: never reporters (52%), 2006 reporters (55%), 2009 reporters
(58%)
Participants: 4,705,857 discharges, 2,580,621 of which were from ’never reporters’,
179,322 from ’2006 reporters’, and 1,945,914 from ’2009 reporters’
Participant age: never reporters (mean 3.5, standard deviation (SD) 5.5), 2006 reporters
(4.4, SD 6.0), 2009 reporters (3.6, SD 5.6)
Participant sex: never reporters (male 54%, female 46%), 2006 reporters (54% male,
46% female), 2009 reporters (55% male, 45% female)
Interventions Intervention: mandatory public reporting of healthcare-associated infections
Control: no mandatory reporting of healthcare-associated infections
Duration: mandatory CLABSI reporting introduced in 2006 or 2009
Deliverer: individual hospitals, as mandated by state legislatures
Funding: unclear
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Rinke 2015 (Continued)
Outcomes Main outcome
• paediatric safety indicator (PDI12), which was defined by the AHRQ as ’selected
infections due to medical care’, and determined using discharge ICD-9-CM codes
99662 (infection due to other vascular device, implant, and graft), 9993 (other
infection), and 99931 (infection due to central venous catheter).
Notes Abbreviations: controlled before-after (CBA) study; Healthcare Cost and Utilization
Project (HCUP); paediatric safety indicator (PDI12); Agency for Healthcare Research
and Quality (AHRQ); International Statistical Classification of Diseases 9th Revision
Clinical Modification (ICD-9-CM)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk CBA study, so did not use random sequence
allocation
Allocation concealment (selection bias) High risk No allocation concealment as hospitals
would have known whether or not their
state mandated public reporting
Adequate blinding of participants, person-
nel and outcome assessors?
High risk No blinding of participants, personnel, or
outcome assessors, as all parties would have
knownwhether or not their statemandated
public reporting
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data for all included hospitals
Selective reporting (reporting bias) Low risk All outcomes and results outlined in the
Method section were reported in tables,
text, or both
Baseline characteristics similar? Low risk Baseline characteristics differed, but were
sufficiently similar to undertake the study
using appropriate analyses
Baseline outcomes similar? Low risk Baseline outcomes differed, but were suffi-
ciently similar to undertake the study using
appropriate analyses (2.4 PDI12 per 1000
discharges in the never-reporting states, 2.
6 in the 2006 reporter states, and 3.0 in the
3009 reporter states)
Protection against contamination High risk Unable to protect against contamination,
as hospitals in states without mandatory
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Rinke 2015 (Continued)
reporting might have been influenced by
states in which these laws were introduced
Other bias Low risk No additional biases identified
Romano 2004
Methods Design: ITS
Country: USA (California and New York)
Care setting: acute hospitals
Duration: California (1991 to 1996), New York (1989 to 1996)
Dataset: California CPDDS, which included discharges from all non-federal hospitals
in the state; New York SPARCS, which was similar in scope to the CPDDS
Total participants: unclear
Unit of analysis: individual patient admissions; accounted for clustering within hospitals
Data analysis: time series ARIMA analysis
Participants Inclusion criteria: adults admitted to acute non-federal hospitals in California and New
York for a target condition, i.e.:
California - target conditions
• AMI
• CABG (AMI-related)
• Percutaneous coronary angioplasty (AMI-related)
• Congestive heart failure (AMI-related)
• Cervical discectomy
• Lumbar discectomy
• Back or neck procedures (discectomy-related)
• Medical back problems (discectomy-related)
• Knee arthroplasty (discectomy-related)
• Hip arthroplasty (discectomy-related)
New York - target conditions
• AMI
• CABG
• Percutaneous coronary angioplasty (AMI-related)
• Congestive heart failure (AMI-related)
Hospital characteristics: no substantial case mix data provided
Participant characteristics: no substantial case mix data provided
Interventions Intervention: California (CHOP following legislation mandating the Office of
Statewide Health Planning and Development to produce annual reports); New York
(New York Cardiac Surgery Reporting System)
Duration: California (first report published in 1993, and second in 1996); New York
(hospital ratings published every 12 to 24 months, from December 1990 until the time
of the study)
Deliverer: report cards were published by agencies in California and New York
Funding: unclear
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Outcomes Main outcome
• Change in the utilisation decisions of consumer, healthcare professional or
purchasers
Notes Abbreviations: interrupted time series (ITS) study; California Patient Discharge Data Set
(CPDDS); Statewide Planning and Research Cooperative System (SPARCS); Autore-
gressive Integrated Moving Average (ARIMA); acute myocardial infarction (AMI); coro-
nary artery bypass grafting (CABG); California Hospital Outcomes Projects (CHOP)
Risk of bias
Bias Authors’ judgement Support for judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data for all included hospitals
Selective reporting (reporting bias) Low risk All outcomes and results outlined in the
Method section were reported in tables,
text, or both
Other bias High risk Main analysis based on the assumption of
same trend before and after intervention;
difference from predicted values was re-
ported, rather than change in trend and
level
Intervention is independent of other
changes? (ITS)
Unclear risk Not stated whether there were other con-
founding events that might have changed
performance over time
Shape of intervention effect pre-specified?
(ITS)
Low risk Quote: ’We therefore hypothesized that
hospitals with lower than expected mortal-
ity or complication rates experience signif-
icant volume increases, and hospitals with
higher than expected mortality or compli-
cation rates experience significant volume
decreases in the year after publication of a
report card’
Knowledge of the interventions adequately
prevented during the study? (ITS)
Low risk Individuals would not have been aware of
the study, as this was performed retrospec-
tively, using administrative data
Intervention unlikely to affect / bias data
collection? (ITS)
Low risk Routinely collected administrative data
that were collected independently of the in-
dividuals at whom the public release of per-
formance data were directed
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Tu 2009
Methods Design: cRT
Country: Canada (Ontario)
Care setting: acute hospitals
Duration: 1 April 2004 to 31 March 2005
Dataset: prospective chart review by research nurses, and study linkage to the Ontario
Registered Persons Vital Statistics Database for mortality outcomes
Total participants: 82 hospital organisations
Unit of allocation: hospital organisations
Unit of analysis: individual patients; accounted for clustering of patientswithinhospitals
Sample size calculation: Quote: ’The study had 84% power to detect 5% absolute
difference on the composite quality indicators. The power calculation assumed a baseline
performance rate on each composite indicator of 70% (standard deviation 10%) in each
study group, and that there would be a secular improvement of 75% (SD 7.5%) in the
composite indicator, independent of the study intervention’
Data analysis: multivariable logistic regression
Participants Inclusion criteria: acute hospitals participating in Ontario, Canada that were identified
from the Canadian Institute for Health Information hospital discharge administrative
database 1999 to 2001 and treated more than 15 patients with acute myocardial infarc-
tion (AMI) annually
Participants: 86 hospital corporations
Institution characteristics: 12% teaching hospitals in the intervention group versus
10% in the control group; 74% community hospitals in the intervention versus 79%
in the control group; 14% small hospitals in the intervention versus 10% in the control
group
AMI patient characteristics: median age 69 (interquartile range 57 to 78) both groups;
female 35.4% versus 36.7%
CHF patient characteristics: median age 77 (interquartile range 70 to 84) versus 77
(69-84); female 51.3% versus 49.2%
Interventions Intervention: report cards with baseline performance data publicly released online and
at a press conference
Control: report cards publicly released after data had been collected, i.e. a delayed release
of data for the control group
Duration: January to 1 April 2004
Deliverer: The Canadian Cardiovascular Outcomes Research Team, which is a national
team of cardiovascular outcomes researchers from across Canada
Funding:Canadian Institutes of Health Research team grant in cardiovascular outcomes
research
Outcomes Main outcomes
• Composite AMI indicators
• Composite CHF indicators
Secondary outcomes
• 12 AMI process-of-care indicators
• 6 CHF process-of-care indicators
• 30-day and 1-year mortality for patients in the following subgroups:
◦ AMI
◦ ST-elevation myocardial infarction (STEMI)
◦ Non-STEMI
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Tu 2009 (Continued)
◦ CHF
◦ CHF with left ventricular dysfunction
Notes Abbreviations: cluster-randomised trial (cRT); acute myocardial infarction (AMI); con-
gestive heart failure (CHF); ST-elevation MI (STEMI)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Method of randomisation not explicitly
stated, but this was undertaken by a ded-
icated study statistician who used a strati-
fied randomisation process
Allocation concealment (selection bias) Low risk Quote ’This random assignment was strat-
ified by type of hospital and performed by
a study statistician’
Adequate blinding of participants, person-
nel and outcome assessors?
High risk Quote: ’It was not possible to blind the hos-
pitals to their status’
Quote: ’We could not blind the delayed
feedback group to the media coverage and
associated publicity surrounding the study
results’
Quote: ’Patient charts were abstracted by
an experienced research nurse’, but it is un-
clear whether or not the nurse was blinded
to allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk One hospital withdrew from the baseline
phase after randomisation, and 4 withdrew
from the follow-up phase, all due to re-
source constraints. No intention-to-treat
analysis was performed. Additional exclu-
sions of patients were not reported
Selective reporting (reporting bias) Low risk A protocol was registered in advance of ran-
domisation and all outcomes were reported
in the final report, which also included a
new outcome (all-cause mortality)
Baseline characteristics similar? Low risk Baseline characteristics of patients and hos-
pitals between the intervention and control
groups were similar
Baseline outcomes similar? Low risk Baseline outcomes presented and varied
between hospitals, although results were
presented as absolute change, and so ac-
43Impact of public release of performance data on the behaviour of healthcare consumers and providers (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Tu 2009 (Continued)
counted for baseline differences
Protection against contamination High risk Quote: ’There was extensive media cover-
age following the release of the baseline per-
formance for the early feedback hospitals’
Quote: ’One unanticipated observation
was that several hospitals in the delayed
feedback group reported that they also ini-
tiated some quality improvement activities
after becoming aware of the publicly re-
leased early feedback report cards, before re-
ceiving their own hospital- specific results’
Other bias Low risk No additional biases identified
Zhang 2016
Methods Design: cRT
Country: China (Hubei Province)
Care setting: primary healthcare institutions
Duration: 2013 to 2014
Dataset: Data collected from patient electronic health records
Total participants: 748,632 outpatient prescriptions from 20 primary healthcare insti-
tutions
Unit of allocation: primary healthcare institutions (paired and matched for similar
characteristics)
Unit of analysis: individual prescriptions; accounted for clustering of prescriptions by
individual prescribers
Sample size calculation: not reported; statistical significance was assessed at the 0.05
level
Data analysis:multivariable regressionmodels, using a difference-in-difference approach
Participants Inclusion criteria: primary care institutions selected from within Qian Jiang City
Primary healthcare institutions: 20 providers, 10 of which were in the intervention
group, and 10 in the control group
Institution characteristics: 60 beds in the intervention group versus 66 in the control
group; 28 versus 26 doctors, 50,199 versus 49,108 annual outpatient visits
Patient characteristics: mean age 37.5 years, 49.5% male
Interventions Intervention: public display of prescription information (percentage of prescriptions
requiring antibiotics, percentage requiring injections, and average patient expenditure)
on outpatient department bulletin boards in participating institutions
Control: no public display of prescription information
Duration: 1 October 2013 to 31 August 2014
Deliverer: outpatient departments of participating institutions
Funding: National Natural Science Foundation of China
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Outcomes Main outcomes
• Percentage of prescriptions requiring antibiotics
• Percentage of prescriptions requiring combined antibiotics
• Percentage of prescriptions requiring injections
• Average expenditure per prescription
Notes Zhang 2016 represents a single study that was reported in five articles (Wang 2014; Yang
2014; Liu 2015; Liu 2016; Tang 2016) that individually satisfied our inclusion criteria.
However, the senior author confirmed that these representedmultiple analyses of a single
cluster-RT (Zhang 2018 [pers comm]). Therefore, we made the decision to present the
cluster-RT (as the original study design and higher level of evidence), rather than the
designs (e.g. CBA and ITS) that were presented in the other articles
Abbreviations: cluster-randomised trial (cRT); controlled before-after (CBA) study; in-
terrupted time series (ITS) study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ’We flipped a coin to randomly as-
sign one (primary care institution) into the
intervention group and another into the
control group’
Allocation concealment (selection bias) High risk Healthcare providers could not be blinded
to the allocation
Adequate blinding of participants, person-
nel and outcome assessors?
High risk It was not possible to blind personnel, who
must have been aware of the group towhich
their primary care institution had been al-
located
Incomplete outcome data (attrition bias)
All outcomes
Low risk Injection prescribing data retrieved from a
comprehensive administrative database
Selective reporting (reporting bias) Low risk All outcomes and results outlined in the
Method section were reported in tables,
text, or both. Although a protocol for the
cRT was published, this appeared eighteen
months after the trial reports stated that the
intervention began
Baseline characteristics similar? Low risk Some baseline characteristics described (e.
g. age and sex), which suggested that the
groups were balanced
Baseline outcomes similar? Low risk Baseline outcomes presented and varied
between hospitals. However, the hospitals
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were paired according to characteristics,
and the results analysed using a differ-
ence-in-difference approach and regression
models to account for residual baseline dif-
ferences
Protection against contamination Unclear risk No statement as to whether or not other
events might have influenced performance
over time
Other bias Low risk No additional biases identified
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Cavender 2015 Cross-sectional study comparing outcomes between states with and without mandatory public reporting
Moscucci 2005 Study design, controlled before-after design; no information reported from the 2 included registries. Not enough
information was reported regarding the baseline data
Paris 2013 Data reported on a private website, so they were not made available to the public
Park 2011 Interrupted time series with insufficient data points
Saratzis 2017 Interrupted time series with insufficient data points
A D D I T I O N A L T A B L E S
Table 1. Summary of included studies
Study detailsa Improvement by selection Improvement by changes in care Data
available
Study De-
sign, set-
ting, and
partici-
pants
Interven-
tion
Con-
sumers
Providers Pur-
chasers
Provider
perfor-
mance
Patient
outcome
Staff
morale
Farley
2002a
cRT; USA;
13,077 in-
surance
plan bene-
Con-
sumer As-
sessment
of Health-
X - - - - - X
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Table 1. Summary of included studies (Continued)
ficiaries care
Providers
and
Systems
(CAHPS)
report
Farley
2002b
cNRT;
USA; 5217
insurance
plan bene-
ficiaries
Con-
sumer As-
sessment
of Health-
care
Providers
and
Systems
(CAHPS)
report
X - - - - - X
Romano
2004
ITS; USA;
-
Report
cards with
risk-ad-
justed pa-
tient out-
comes pro-
duced by
state agen-
cies
X - - - - - b
Flett 2015 ITS; USA;
21 hospi-
tals
State-
based
mandatory
public re-
porting of
healthcare-
associated
infections
- X - - - - X
Rinke
2015
CBA;
USA; 3207
hospitals
Manda-
tory public
reporting
of health-
care-asso-
ciated in-
fections
- - - - X - X
DeVore
2016
ITS;
USA; 315,
092 hospi-
talisations
Online re-
porting
of risk-ad-
justed 30-
day re-ad-
- - - - X - b
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Table 1. Summary of included studies (Continued)
mission
rates (Hos-
pital Com-
pare)
Joynt 2016 ITS; USA;
3970 hos-
pitals
Online re-
porting
of risk-ad-
justed 30-
day
mortality
rates (Hos-
pital Com-
pare)
- - - - X - X
Liu 2017 ITS; USA;
244 hospi-
tals
Manda-
tory public
reporting
of health-
care-asso-
ciated in-
fections
- - - - X - -c
Tu 2009 cRT;
Canada;
82 hospi-
tal organi-
sations
Report
cards with
risk-ad-
justed pa-
tient out-
comes
and a press
conference
- - - X X - X
Jang 2011 ITS; South
Korea; 3,
000,000
live births
Repeated
public re-
lease of in-
formation
(on-
line, press
releases)
on hospital
caesarean
rates
- X - - - - X
Ikker-
sheim
2013
cRT; The
Nether-
lands; 26
gen-
eral practi-
tioners
Report
cards with
risk-ad-
justed pa-
tient out-
comes sent
- X - - - - b
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Table 1. Summary of included studies (Continued)
to GPs for
discus-
sion with
patients
Zhang
2016
cRT;
China; 20
pri-
mary care
providers
Public dis-
play of pre-
scrip-
tion infor-
mation on
out-
patient de-
partment
bulletin
boards
- X - - - - X
controlled before-after (CBA) study; cluster-randomised trial (cRT); cluster-non-randomised trial (cNRT); Consumer Assessment of
Healthcare Providers and Systems (CAHPs); general practitioners (GPs); interrupted time series (ITS) study
Column headers: changes in healthcare utilisation by consumers (Consumers); changes in healthcare decisions taken by healthcare
providers (professionals and organisations; (Providers)); changes in healthcare decisions of purchasers (Purchasers); changes in provider
performance (Provider performance); changes in patient outcome (Patient outcome); changes in staff morale (Staff morale); impact on
equity (Equity)
Order of studies: listed in chronological order USA, then chronological order for other countries of study
a Studies grouped by intervention, i.e. mode of public release of performance data
b No change in slope and so re-analysis of the ITS data was uninformative
c Presented derived data (e.g. outputs of regression models) that were insufficient for re-analysis
Table 2. Changes in the healthcare utilisation decisions of consumers
Intervention Outcome Study Type of study Abso-
lute post-in-
tervention
difference
Absolute pre-
intervention
difference
Post-
intervention
level in con-
trol group
Relative effect
Dis-
semination of
consumer re-
ports directly
to consumers
Assigned
to high-rated
HMO (2
choices)
Farley 2002a cRT 1.5 0 15.9 0.0943
As-
signed to low-
rated HMO
(2 options)
0.4 0 25 0.0160
Assigned
to high-rated
HMO (1 op-
tion)
1.3 0 29.5 0.0441
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Table 2. Changes in the healthcare utilisation decisions of consumers (Continued)
As-
signed to low-
rated HMO
(1 option)
0.1 0 23.7 0.0042
Proportion
choosing plan
Farley 2002b cNRT 0.01 0 0.69 0.0145
cluster-randomised trial (cRT); cluster-non-randomised trial (cNRT); health maintenance organization (HMO)
Table 3. Changes in the healthcare utilisation decisions of healthcare providers (professionals and organisations)
Interven-
tion
Outcome Study Type of
study
Absolute
post-in-
tervention
difference
Absolute
pre-inter-
vention
difference
Post-
interven-
tion level
in control
group
Relative
effect
Public re-
porting of
injection
prescrib-
ing rates in
outpatient
areas
Average ex-
penditure
per pre-
scription
Zhang
2016
cRT 3.4 2.2 41.2 0.0291
Percent-
age of pre-
scriptions
requiring
antibiotics
4.6 6.1 62.8 -0.0249
Percent-
age of pre-
scriptions
requiring
combined
antibiotics
2.1 4.1 18.6 -0.1083
Percent-
age of pre-
scriptions
requiring
injections
9.0 13.2 64.9 -0.0643
Average ex-
penditure
per pre-
scription
7.2 6.9 44.3 0.0070
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Table 3. Changes in the healthcare utilisation decisions of healthcare providers (professionals and organisations) (Continued)
Manda-
tory public
reporting
of health-
care-asso-
ciated in-
fections
Pediatric
quality in-
dicator per
1000 eligi-
ble
discharges
Rinke
2015
CBA 0.6 0.5 1.0 0.1000
Interven-
tion
Outcome Study Type of
study
Absolute
level effect
(95% CI)
Relative
change at
3 months
(95% CI)
Relative
change at
6 months
(95% CI)
Relative
change at
9 months
(95% CI)
Relative
change at
12
months
(95% CI)
Relative
change at
24
months
(95% CI)
Repeated
public re-
lease
of hospital
cae-
sarean sec-
tion rates
Cae-
serean sec-
tion rate
Jang 2011 ITS -0.52 (-0.
77 to -0.
26)
-0.04 (-1.
23 to 1.18)
-1.49 (-2.
55 to -0.
40)
-2.92 (-4.
50 to 1.30)
-4.34 (-6.
61 to -1.
95)
-
Manda-
tory public
reporting
of health-
care-asso-
ciated in-
fections
PICU
blood cul-
tures
Flett 2015 ITS 7.48 (1.09
to 13.87)
6.21 (-
2.84 to 17.
10)
9.90 (-
0.45 to 22.
64)
13.
87 (1.42 to
29.82)
18.
17 (2.90 to
38.77)
22.
87 (4.11 to
49.86)
PICU an-
tibiotics
7.29 (4.46
to 10.12)
-0.11 (-2.
03 to 1.89)
1.61 (-0.
45 to 3.75)
3.36 (0.96
to 5.87)
5.15 (2.26
to 8.20)
6.98 (2.50
to 10.70)
NICU an-
tibiotics
-5.79 (-9.
17 to -2.
42)
8.12 (4.
11-12.46)
6.06 (2.08
to 10.35)
4.05 (-0.
35 to 8.85)
1.90 (-3.
17 to 7.53)
-0.36 (-6.
25 to 6.33)
NICU
blood cul-
tures
-1.14 (-1.
90 to -0.
39)
2.49 (-0.
51 to 5.67)
1.06 (-2.
07 to 4.39)
-0.42 (-3.
93 to 3.36)
-1.95 (-6.
02 to 2.49)
-3.53 (-8.
26 to 1.72)
cluster-randomised trial (cRT); controlled before-after (CBA) study; 95% confidence interval (95% CI); interrupted time series (ITS)
study; neonatal intensive care unit (NICU); paediatric intensive care unit (PICU)
Table 4. Changes in provider performance
Intervention Outcome Study Type of study Absolute post-
intervention
difference
Abso-
lute pre-inter-
vention differ-
ence
Postinterven-
tion level in
control group
Relative effect
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Table 4. Changes in provider performance (Continued)
Public release
of a range of
quality indica-
tors
All AMI pro-
cesses
Tu 2009 cRT 2.0 0.9 65.6 0.0168
Use of stan-
dard admis-
sion orders
6.1 0.7 72.5 0.0745
Left ventricu-
lar function
assessment
2.9 6.3 49.8 -0.0683
Lipid test < 24
hours arrival
3.8 1.6 51.1 0.0431
Fibrinolytics <
30 mins after
arrival
2.6 3.1 45.7 -0.0109
Fibrinolyt-
ics decided by
ED physician
2.0 4.4 84.3 -0.0285
Fibrinolytics
prior to trans-
fer to CCU
3.8 2.9 95.7 0.0094
Aspirin < 6
hours arrival
5.5 3.1 82.6 0.0291
B blockers <
12 hours ar-
rival
2.4 3.9 73.7 -0.0204
Aspirin at dis-
charge
0.9 0.0 84.0 0.0107
B blockers at
discharge
0.6 0.0 85.6 0.0070
ACEi,
ARB for LV
dysfunction
4.7 3.4 81.7 0.0159
Statin at dis-
charge
0.3 0.2 85.5 0.0012
All CHF pro-
cesses
1.0 3.0 54.6 -0.0366
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Table 4. Changes in provider performance (Continued)
LVF
assessment
2.7 4.5 55.2 -0.0326
Daily weights
recorded
1.3 0.3 24.0 0.0417
Coun-
selling on > 1
aspect of CHF
0.9 1.7 55.3 -0.0145
ACEi,
ARB for LV
dysfunction
6.3 1.7 92.4 0.0498
B blockers for
LV
dysfunction
4.0 1.7 71.7 0.0321
Warfarin for
AF
0.6 3.1 64.2 -0.0389
atrial fibrillation (AF); acute myocardial infarction (AMI); angiotensin-converting enzyme inhibitor (ACEi); angiotensin-2 receptor
blockers (ARB); beta-adrenergic blocking agents (B blockers); cluster-randomised trial (cRT); coronary care unit (CCU); congestive
heart failure (CHF); emergency department (ED); left ventricular (LV); left ventricular failure (LVF); minutes (mins)
Table 5. Changes in patient outcome
Interven-
tion
Outcome Study Type of
study
Absolute
postinter-
vention dif-
ference
Absolute
pre-inter-
vention dif-
ference
Postinter-
vention
level in con-
trol group
Relative ef-
fect
Pub-
lic release of
a range of
quality indi-
cators
AMI 30-day
mortality
Tu 2009 cRT 2.4 0.5 9.8 0.1939
AMI 1-year
mortality
3.1 1 19.4 0.1082
STEMI 30-
day mortal-
ity
3.1 0.4 8.3 0.3253
STEMI 1-
year mortal-
ity
3.9 1.2 13.5 0.2000
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Table 5. Changes in patient outcome (Continued)
NSTEMI
30-day mor-
tality
2.3 0.3 10.5 0.1905
NSTEMI 1-
year mortal-
ity
3 0.9 22.6 0.0929
CHF
30-day mor-
tality
1 0.9 9.6 0.0104
CHF 1-year
mortality
2.6 0.6 30.3 0.0660
CHF and
LV dysfunc-
tion 30-day
mortality
0.9 0.6 8.5 0.0353
CHF
and LV dys-
function 1-
year mortal-
ity
6.3 1.8 26.3 0.1711
Mandatory
reporting of
healthcare-
associated
infections
Pe-
diatric qual-
ity indicator
per 1000 el-
igible
discharges
Rinke 2015 CBA 0.6 0.5 1 0.1000
Interven-
tion
Outcome Study* Type of
study
Ab-
solute level
effect (95%
CI)
Rela-
tive change
at 4 months
(95% CI)
Rela-
tive change
at 8 months
(95% CI)
Relative
change at
12 months
(95% CI)
Relative
change at
24 months
(95% CI)
Hospital
quality pro-
cess and out-
come met-
rics reported
on a public
website
30-day risk-
adjusted
mortality
Joynt 2016 ITS 0.12 (0.03
to 0.21)
1.57 (-4.28
to 8.18)
-2.47 (-8.20
to 4.03)
3.71 (-3.25
to 11.74)
7.18 (-1.91
to 18.13)
Pub-
lic reporting
30-day re-
admission
DeVore
2016
ITS 0.00 (0.00
to 0.00)
-2.04 (-8.56
to 5.48)
-1.36 (-7.92
to 6.20)
-0.69 (-7.34
to 7.00)
0.72 (-6.32
to 8.90)
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Table 5. Changes in patient outcome (Continued)
of risk-stan-
dardised
hospi-
tal re-admis-
sion rates
(AMI)
30-day re-
admission
(heart
failure)
0.00 (0.00
to 0.00)
-1.39 (-4.17
to 1.56)
-1.84 (-4.59
to 1.08)
-1.88 (-4.68
to 1.10)
-2.78 (-6.42
to 1.15)
30-day re-
admis-
sion (pneu-
monia)
0.00 (0.00
to 0.00)
-4.44 (-13.
61 to 6.91)
-5.07 (-14.
17 to 6.20)
-5.69 (-14.
71 to 5.47)
-7.45 (-18.
10 to 6.37)
30-day re-
admission
(COPD)
0.00 (0.00
to 0.00)
-6.66 (-11.
42 to -1.37)
-0.76 (-6.11
to 5.23)
-7.64 (-12.
31 to -2.44)
-9.06 (-13.
62 to -4.00)
30-day re-
admission
(diabetes)
0.00 (-0.00
to 0.01)
-0.65 (-13.
66 to 16.96)
0.00 (-13.13
to 17.81)
0.65 (-12.44
to 18.35)
1.98 (-13.57
to 24.36)
30-day mor-
tality (AMI)
0.00 (0.00
to 0.00)
34.38 (2.71
to 94.32)
35.83 (2.79
to 100.17)
37.38 (2.88
to 106.67)
43.06 (3.20
to 133.08)
30-day mor-
tality (heart
failure)
0.00 (0.00
to 0.00)
6.04 (-5.86
to 21.37)
13.78 (-0.56
to 32.94)
9.98 (-3.46
to 27.77)
13.31 (-0.54
to 31.64)
30-day mor-
tality (pneu-
monia)
0.00 (0.00
to 0.00)
-3.96 (-23.
10 to 27.85)
-3.72 (-16.
70 to 14.05)
2.94 (-18.04
to 19.00)
-3.84 (-22.
51 to 26.69)
30-day mor-
tality
(COPD)
0.00 (0.00
to 0.00)
20.89 (5.51
to 41.52)
21.63 (5.68
to 43.24)
20.99 (5.54
to 41.75)
22.00 (5.77
to 44.13)
30-day mor-
tality
(diabetes)
0.00 (0.00
to 0.00)
-14.73 (-34.
83 to 23.29)
-15.10 (-35.
48 to 24.12)
-14.78 (-34.
92 to 23.40)
-19.39 (-42.
65 to 35.66)
Acute Myocardial Infarction (AMI); ST-Elevation Myocardial Infarction (STEMI); Non-ST-Elevation Myocardial Infarction
(NSTEMI); Congestive Heart Failure (CHF); Left Ventricular (LV); Chronic Obstructive Pulmonary Disease (COPD); Cluster
Randomised Trial (cRT); Controlled Before-After (CBA) study; Interrupted Time Series (ITS) study; 95% Confidence Interval
(95% CI)
* Joynt 2016 and DeVore 2016 provided outcomes in quarters rather than months and so have been presented as 4- and 8-months
rather than the pre-specified 3- and 6-months.
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A P P E N D I C E S
Appendix 1. Search strategies
The Cochrane Library
No. Search terms Results
#1 [mh “quality indicators, health care”] 430
#2 (performance next outcome):ti,ab 27
#3 (quality near/2 indicator*) 774
#4 (quality next (criteria or criterion or standard* or norm*)) 7150
#5 (performance next (indicator* or measure* or data or rating*
or information))
1580
#6 {or #1-#5} 9538
#7 [mh “patient satisfaction”] 11006
#8 [mh “consumer behavior”] 704
#9 [mh “consumer participation”] 1328
#10 [mh “patient acceptance of health care”] 25536
#11 [mh “decision making”] 3661
#12 [mh “choice behavior”] 1181
#13 (patient next (satisfaction or preference*)):ti,ab 7724
#14 (consumer next report*):ti,ab 3
#15 (decision next making):ti,ab 5100
#16 (choice next behavio*):ti,ab 54
#17 (provider next profiling):ti,ab 0
#18 {or #7-#17} 38104
#19 #6 and #18 531
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(Continued)
#20 (“Consumer Assessment of Healthcare Providers and Systems”
or CAHPS):ti,ab
44
#21 (public next (disclosure or release)):ti,ab 26
#22 ((public or publically or publicly) near/3 (report* or report-
card*)):ti,ab
168
#23 ((public or publically or publicly or publication* or publish* or
release) near/3 quality near/2 (information or data or report*
or criteria or criterion or standard* or norm* or indicator*)):
ti,ab
58
#24 ((public or publically or publicly or publication* or publish*
or release) near/3 (performance or hospital) next (data or in-
dicator* or measure* or rating* or information or outcome)):
ti,ab
8
#25 ((publication* or publish*) near/3 (report card* or reportcard*)
):ti,ab
0
#26 ((public or publically or publicly or release) near/3 (waiting
time* or waiting list* or outcome* or mortality or certification
or accreditation)):ti,ab
154
#27 {or #19-#26} 962
MEDLINE OVID
including Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Versions
No. Search terms Results
1 quality indicators, health care/ 13425
2 performance outcome.ti,ab. 312
3 (quality adj2 indicator?).tw. 7698
4 (quality adj (criteria or criterion or standard? or norm*)).tw 8898
5 (performance adj (indicator? or measure? or data or rating? or
information)).tw
13724
6 or/1-5 39819
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(Continued)
7 exp patient satisfaction/ 77553
8 consumer behavior/ 19767
9 exp consumer participation/ 37908
10 exp “patient acceptance of health care”/ 211344
11 decision making/ 82537
12 choice behavior/ 27969
13 (patient adj (satisfaction or preference?)).ti,ab. 34638
14 consumer report*.ti,ab. 171
15 decision making.ti,ab. 99376
16 choice behavio?r.ti,ab. 1225
17 provider profiling.ti,ab. 68
18 or/7-17 420568
19 6 and 18 3693
20 (“Consumer Assessment of Healthcare Providers and Systems”
or CAHPS).ti,ab
536
21 (public adj (disclosure or release)).ti,ab. 465
22 ((public or publicly or publicly) adj3 (report* or reportcard*)
).ti,ab
7360
23 ((public or publicly or publicly or publication* or publish* or
release) adj3 quality adj2 (information or data or report* or
criteria or criterion or standard? or norm* or indicator?)).ti,ab
727
24 ((public or publically or publicly or publication* or publish* or
release) adj3 (performance or hospital) adj (data or indicator?
or measure? or rating? or information or outcome)).ti,ab
210
25 ((publication* or publish*) adj3 (report card* or reportcard*)
).ti,ab
20
26 ((public or publically or publicly or release) adj3 (waiting time*
or waiting list* or outcome* or mortality or certification or
accreditation)).ti,ab
2092
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(Continued)
27 or/19-26 14336
28 intervention?.ti. or (intervention? adj6 (clinician? or collabo-
rat* or community or complex or design* or doctor? or edu-
cational or family doctor? or family physician? or family prac-
titioner? or financial or GP or general practice? or hospital? or
impact? or improv* or individuali?e? or individuali?ing or in-
terdisciplin* or multicomponent or multi-component or mul-
tidisciplin* or multi-disciplin* or multifacet* or multi-facet*
or multimodal* or multi-modal* or personali?e? or personali?
ing or pharmacies or pharmacist? or pharmacy or physician?
or practitioner? or prescrib* or prescription? or primary care
or professional* or provider? or regulatory or tailor* or target*
or team* or usual care)).ab
242637
29 (pre-intervention? or preintervention? or “pre intervention?”
or post-intervention? or postintervention? or “post interven-
tion?”).ti,ab
17765
30 (hospital* or patient?).hw. and (study or studies or care or
health* or practitioner? or provider? or physician? or nurse? or
nursing or doctor?).ti,hw
860541
31 demonstration project?.ti,ab. 2366
32 (pre-post or “pre test*” or pretest* or posttest* or “post test*”
or (pre adj5 post)).ti,ab
96293
33 (pre-workshop or post-workshop or (before adj3 workshop)
or (after adj3 workshop)).ti,ab
929
34 trial.ti. or ((study adj3 aim?) or “our study”).ab. 938722
35 (before adj10 (after or during)).ti,ab. 441395
36 (“quasi-experiment*” or quasiexperiment* or “quasi random*”
or quasirandom* or “quasi control*” or quasicontrol* or (
(quasi* or experimental) adj3 (method* or study or trial or
design*))).ti,ab
131481
37 non-randomized controlled trials as topic/ 169
38 pilot projects/ 104980
39 pilot.ti. or (pilot adj (project? or study or trial)).ab. 93665
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(Continued)
40 (time points adj3 (over ormultiple or three or four or five or six
or seven or eight or nine or ten or eleven or twelve or month*
or hour? or day? or “more than”)).ab
14152
41 (“time series” adj2 interrupt*).ti,ab. 1859
42 interrupted time series analysis/ 298
43 controlled before-after studies/ 256
44 historically controlled study/ 121
45 (multicentre or multicenter or multi-centre or multi-center).
ti
42227
46 (control adj3 (area or cohort? or compare? or condition or
design or group? or intervention? or participant? or study)).ab
626900
47 random*.ti,ab. or controlled.ti. 1014934
48 (control year? or experimental year? or (control period? or ex-
perimental period?)).ti,ab
15687
49 (utili?ation or programme or programmes).ti. 68459
50 (during adj5 period).ti,ab. 365550
51 ((strategy or strategies) adj2 (improv* or education*)).ti,ab 28012
52 (clinical trial or multicenter study).pt. 698767
53 evaluation studies as topic/ or prospective studies/ or retro-
spective studies/
1219000
54 ((evaluation or prospective or retrospective) adj study).ti,ab 237086
55 or/28-54 5017158
56 “comment on”.cm. or review.pt. or (review not “peer review*”)
.ti. or randomized controlled trial.pt
3590916
57 (rat or rats or cow or cows or chicken? or horse or horses or
mice or mouse or bovine or animal?).ti,hw. or veterinar*.ti,ab,
hw
6283639
58 exp animals/ not humans.sh. 4421689
59 or/56-58 9133273
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(Continued)
60 55 not 59 3575771
61 exp randomized controlled trial/ 467146
62 controlled clinical trial.pt. 94240
63 randomi#ed.ti,ab. 523398
64 placebo.ab. 190671
65 drug therapy.fs. 2009566
66 randomly.ti,ab. 284535
67 trial.ab. 428718
68 groups.ab. 1746590
69 or/61-68 4163334
70 Clinical Trials as topic.sh. 186965
71 trial.ti. 183461
72 or/61-64,66,70-71 1182798
73 exp animals/ not humans/ 4421689
74 72 not 73 1092643
75 60 or 74 4276001
76 27 and 75 5296
Embase OVID
1974 to 2017 June 23
No. Search terms Results
1 *health care quality/ 68159
2 performance outcome.ti,ab. 342
3 (quality adj2 indicator?).tw. 10919
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(Continued)
4 (quality adj (criteria or criterion or standard? or norm*)).tw 12871
5 (performance adj (indicator? or measure? or data or rating? or
information)).tw
17408
6 or/1-5 104870
7 *patient satisfaction/ 19552
8 *consumer attitude/ 1238
9 *consumer/ 13586
10 exp *patient attitude/ 77273
11 exp *decision making/ 64896
12 (patient adj (satisfaction or preference?)).ti,ab. 47403
13 consumer report*.ti,ab. 224
14 decision making.ti,ab. 125401
15 choice behavio?r.ti,ab. 1259
16 provider profiling.ti,ab. 78
17 or/7-16 289262
18 6 and 17 6609
19 (“Consumer Assessment of Healthcare Providers and Systems”
or CAHPS).ti,ab
688
20 (public adj (disclosure or release)).ti,ab. 539
21 ((public or publically or publicly) adj3 (report* or reportcard*)
).ti,ab
4867
22 ((public or publically or publicly or publication* or publish*
or release) adj3 quality adj2 (information or data or report* or
criteria or criterion or standard? or norm* or indicator?)).ti,ab
925
23 ((public or publically or publicly or publication* or publish* or
release) adj3 (performance or hospital) adj (data or indicator?
or measure? or rating? or information or outcome)).ti,ab
260
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(Continued)
24 ((publication* or publish*) adj3 (report card* or reportcard*)
).ti,ab
25
25 ((public or publically or publicly or release) adj3 (waiting time*
or waiting list* or outcome* or mortality or certification or
accreditation)).ti,ab
2577
26 or/18-25 15596
27 intervention?.ti. or (intervention? adj6 (clinician? or collabo-
rat* or community or complex or design* or doctor? or edu-
cational or family doctor? or family physician? or family prac-
titioner? or financial or GP or general practice? or hospital? or
impact? or improv* or individuali?e? or individuali?ing or in-
terdisciplin* or multicomponent or multi-component or mul-
tidisciplin* or multi-disciplin* or multifacet* or multi-facet*
or multimodal* or multi-modal* or personali?e? or personali?
ing or pharmacies or pharmacist? or pharmacy or physician?
or practitioner? or prescrib* or prescription? or primary care
or professional* or provider? or regulatory or tailor* or target*
or team* or usual care)).ab
311084
28 (pre-intervention? or preintervention? or “pre intervention?”
or post-intervention? or postintervention? or “post interven-
tion?”).ti,ab
23998
29 (hospital* or patient?).hw. and (study or studies or care or
health* or practitioner? or provider? or physician? or nurse? or
nursing or doctor?).ti,hw
2331637
30 demonstration project?.ti,ab. 2749
31 (pre-post or “pre test*” or pretest* or posttest* or “post test*”
or (pre adj5 post)).ti,ab
150055
32 (pre-workshop or post-workshop or (before adj3 workshop)
or (after adj3 workshop)).ti,ab
1380
33 trial.ti. or ((study adj3 aim?) or “our study”).ab. 1333514
34 (before adj10 (after or during)).ti,ab. 576316
35 (“quasi-experiment*” or quasiexperiment* or “quasi random*”
or quasirandom* or “quasi control*” or quasicontrol* or (
(quasi* or experimental) adj3 (method* or study or trial or
design*))).ti,ab
148541
36 quasi experimental study/ 3847
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(Continued)
37 *experimental design/ or *pilot study/ 12503
38 pilot.ti. or (pilot adj (project? or study or trial)).ab. 127487
39 (time points adj3 (over ormultiple or three or four or five or six
or seven or eight or nine or ten or eleven or twelve or month*
or hour? or day? or “more than”)).ab
20189
40 (“time series” adj2 interrupt*).ti,ab. 2195
41 (multicentre or multicenter or multi-centre or multi-center).
ti
60391
42 (control adj3 (area or cohort? or compare? or condition or
design or group? or intervention? or participant? or study)).ab
838775
43 random*.ti,ab. or controlled.ti. 1272455
44 (control year? or experimental year? or (control period? or ex-
perimental period?)).ti,ab
18126
45 (utili?ation or programme or programmes).ti. 84680
46 (during adj5 period).ti,ab. 479514
47 ((strategy or strategies) adj2 (improv* or education*)).ti,ab 35217
48 *clinical trial/ or *multicenter study/ 22311
49 *evaluation study/ or *prospective study/ or *retrospective
study/
17721
50 ((evaluation or prospective or retrospective) adj study).ti,ab 334438
51 or/27-50 6068150
52 (rat or rats or cow or cows or chicken? or horse or horses or
mice or mouse or bovine or animal?).ti
1706244
53 (exp animal/ or exp invertebrate/ or animal experiment/ or
animal model/ or animal tissue/ or animal cell/ or nonhuman/
or exp eperimental animal/) not (human/ or normal human/
or human cell/)
6203744
54 or/52-53 6406291
55 51 not 54 5294553
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(Continued)
56 random*.ti,ab. 1208834
57 factorial*.ti,ab. 30632
58 (crossover* or cross over*).ti,ab. 88860
59 ((doubl* or singl*) adj blind*).ti,ab. 197702
60 (assign* or allocat* or volunteer* or placebo*).ti,ab. 850967
61 crossover procedure/ 52055
62 single blind procedure/ 27932
63 randomized controlled trial/ 458261
64 double blind procedure/ 140193
65 or/56-64 1880362
66 exp animal/ not human/ 4805839
67 65 not 66 1685252
68 55 or 67 5737909
69 26 and 68 9702
ClinicalTrials.gov
Search terms Results
performance indicator AND public AND behaviour 6
quality indicator AND public AND behaviour 21
performance data AND public AND behaviour 31
performance measure AND public AND behaviour 52
performance rating AND public AND behaviour 36
performance information AND public AND behaviour 37
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WHO International Clinical Trials Registry Platform (ICTRP)
Search terms Results
quality AND public AND behaviour 15
performance AND public AND behaviour 5
Appendix 2. Certainty of the evidence
No of studies De-
sign
Risk of bias Inconsis-
tency
Indirect-
ness
Impreci-
sion
Other Certainty
(overall score)
Outcome: Changes in healthcare utilisation by consumers
3 1 RT
1
NRT
1 ITS
0 0 0 0 0 Low
Studies: Farley 2002a,
Farley 2002b, Romano
2004
No cause to increase or decrease level of confidence.
Outcome: Changes in healthcare decisions taken by healthcare providers (professionals and organisations)
4 2 RT
2 ITS
Initial: 3
Final: 3
-1* 0 0 0 Low
Studies: Flett 2015; Ikkersheim 2013;
Jang 2011; Zhang 2016
* -1 for inconsistency as Zhang 2016 showed a change in
behaviour, which was not consistently observed throughout
the other 3 studies
Outcome: Changes in healthcare decisions taken by healthcare purchasers
0 0 0 0 0 0 0 -
Studies: None
Outcome: Changes in provider performance
1 1 RT -2* 0 0 0 0 Low
Studies: Tu 2009 * -2 for risk of bias as there was attrition of participating hospitals, evidence of contamination of
the intervention across intervention and control hospitals, and blinding was not possible given the
nature of the intervention
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(Continued)
Outcome: Changes in patient outcome
5 1 RT
3 ITS
1 CBA
0 -2* 0 0 0 Low
Studies: DeVore 2016; Joynt
2016; Liu 2017; Rinke 2015;
Tu 2009
* -2 for inconsistency as there was marked disagreement between studies with two showing improve-
ments in patient outcome (Tu 2009, Liu 2017) and three showing no such improvements (DeVore
2016, Joynt 2016, Rinke 2015).
Outcome: Changes in staff morale
0 0 0 0 0 0 0 -
Studies: None
Outcome: Adverse effects
0 0 0 0 0 0 0 -
Studies: None
Outcome: Impact on equity
1 1 ITS 0 0 0 0 0 Low
Studies: Romano 2004 No cause to increase or decrease level of confidence.
WH A T ’ S N E W
Last assessed as up-to-date: 26 June 2017.
Date Event Description
3 April 2018 New search has been performed This is the first update of this review. We updated the
searches to June 2017, and identified 8 new studies. The
review now includes 12 studies. The ’Risk of bias’ as-
sessments, data extraction, and data synthesis were un-
dertaken for all 12 studies, to bring the review into line
with the latest Effective Practice and Organisation of
Care (EPOC) guidelines. Four authors (Marjan Faber,
Liv Rygh, Katherine Deane, and Martin Eccles) left the
original co-author team, and were replaced by five others
(David Metcalfe, Arturo Rios Diaz, Olubode Olufajo,
Sofia Massa, and Daniel Perry)
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(Continued)
29 March 2018 New citation required but conclusions have not changed The conclusion that the evidence base is inadequate to
directly informpolicy and practice has not changed since
the last version of this review
H I S T O R Y
Protocol first published: Issue 4, 2003
Review first published: Issue 11, 2011
Date Event Description
21 August 2008 New citation required and minor changes Comments on protocol.
4 April 2008 Amended Converted to new review format.
12 August 2003 New citation required and major changes Substantive amendment.
C O N T R I B U T I O N S O F A U T H O R S
DM coordinated this update and drafted the review, with guidance from DP. NK, and SF were co-authors on an earlier version, and so
helped develop the study protocol. DM, ARD, and OO undertook study selection for the updated review, extracted and re-analysed
study data, and performed the ’Risk of bias’ assessments. DM and SM undertook the statistical analysis. All authors made critical
revisions to the manuscript.
D E C L A R A T I O N S O F I N T E R E S T
DM: None known
NK: None known
ARD: None known
OO: None known
SF: None known
SM: None known
DP: None known
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S O U R C E S O F S U P P O R T
Internal sources
• University of Newcastle upon Tyne, UK.
External sources
• UK National Institute for Health Research Cochrane Programme Grant, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the protocol, we listed types of participants as healthcare providers, which included hospitals, practices, and individual health
professionals. Patients and other healthcare consumers and purchasers of health care were also target groups for the aims and scopes
of performance measurements. We added these types to the list of participants, so it should be mentioned here, but should not be
considered a change of protocol. We mentioned patients, other healthcare consumers, and purchasers in the protocol description of
outcome measures, but they were missing in the types of participants. We solved this inconsistency in the review by adding these
types of participants. We did not present funnel plots as there were not more than 10 studies contributing to any given analysis, as
recommended by Higgins 2011. We had planned to report the findings of included studies that also included data on awareness,
knowledge of performance data, attitude, and cost data. However, there were substantial difficulties in presenting such data from two
studies due to inadequate survey response (Farley 2002b) and poor reporting (Ikkersheim 2013) and so these data were not presented.
Since the publication of the protocol, the Effective Practice and Organisation of Care (EPOC) Group has adjusted the definitions for
the quality criteria. In the review, we used the latest version of the ‘Risk of bias’ tables to assess the included studies (EPOC 2013). We
also revised our use of study design nomenclature and handling of data (including re-analysis), in line with the latest EPOC guidance.
Similarly, we reported the certainty of evidence provided by each group of studies using the GRADE criteria, and we included a
’Summary of findings’ table. We also updated the outcomes to include ’adverse events’ and ’equity’ as recommended by the EPOC
Group. As two included studies presented data in quarter years rather than months, we reported outcomes at 4- and 8-months rather
than 3- and 6-months for these studies in Table 5 (DeVore 2016; Joynt 2016).
The original version of this review was published by Nicole Ketelaar, Marjan Faber, Signe Flottorp, Liv Rygh, Katherine Deane, and
Martin Eccles (Ketelaar 2011). MF, LR, KD, and ME have since left the author team, and been replaced by David Metcalfe, Arturo
Rios Diaz, Olubode Olufajo, Sofia Massa, and Daniel Perry.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Information Dissemination; ∗Quality Improvement; Canada; Consumer Health Information [∗methods]; Evaluation Studies as Topic;
Health Maintenance Organizations [standards]; Hospitals [∗standards]; Medicaid; Organizational Innovation; Quality Assurance,
Health Care [∗methods]; Randomized Controlled Trials as Topic; Reproducibility of Results; United States
MeSH check words
Humans
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